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Abstract 
Background: Worldwide, prostate cancer (PCa) is the most commonly diagnosed non-skin 
cancer in men. The current diagnostic standard of PCa requires invasive procedures such as needle 
biopsies. Non-invasive medical imaging techniques, such as Computed Tomography (CT), are 
only used as an adjunct for staging PCa. The development of a novel non-invasive imaging 
technique for PCa could revolutionize diagnostic standards and improve patient prognosis. The 
similarity between canine and human prostates, as well as similar PCa pathophysiology, makes the 
dog an ideal model for human PCa research. Initial investigations with Phase Contrast – CT (PC-
CT) has shown potential for detecting morphological abnormalities in ex vivo canine prostates and 
therefore warrants further testing as a potential PCa diagnostic imaging technique. 
 
This research addresses the design, development and implementation of a canine positioning device 
used for in situ prostate PC-CT imaging on the Biomedical Imaging and Therapy –Insertion Device 
Beamline at the Canadian Light Source. This device is currently being used to collect micron-level 
resolution PC-CT reconstructions of canine cadaver prostates. This thesis lays the ground work for 
canine imaging on the BMIT – ID beamline at the CLS. The design and implementation of the 
device are described, along with the issues discovered and addressed.  
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Chapter 1: Introduction 
1.1 Overview 
In Canada and worldwide, prostate cancer (PCa) is the most commonly diagnosed non-
skin cancer in men (3). It is estimated that in 2015 approximately 24% of all new cancer cases in 
men will be PCa. In Canada, PCa is the third leading cause of cancer deaths in men. When PCa 
is detected in the early stage of the disease the five-year relative survival rate is 96%, meaning 
that most men will die with PCa, but not due to PCa. Unfortunately, if PCa is detected in the later 
stages of the disease, the five-year relative survival rate drops to around 31% (3). Therefore, the 
early detection of PCa is key to a favorable prognosis.  
The current diagnostic strategy of PCa involves multiple invasive tests, usually needle 
biopsies, which are not 100% accurate (4). The false negative rate for prostate biopsy is between 
20-24% (5), (6). The probability of detecting PCa using needle biopsies is subject to random 
sampling error, and introduces doubts about diagnostic accuracy (7). Needle biopsies also come 
with a variety of risks including hematuria, infection, hospital admission and even death (4). 
Unfortunately, the diagnostic gold standard of PCa is histological evaluation, which requires an 
invasive biopsy to obtain prostate tissue (4), (8). 
Currently non-invasive medical imaging techniques, such as Magnetic Resonance 
Imaging (MRI), Computed Tomography (CT) and Ultrasound (US) are only used as an adjunct 
for staging PCa (7). Low image resolution with conventional medical imaging modalities 
prevents clear distinction between intra-organ tissue types and cellular morphologies, preventing 
pathologists from visually diagnosing PCa (9). In the past twenty years, synchrotron X-ray 
imaging has emerged as a novel way for high resolution imaging of biological tissues and 
samples (10), (11), (12).  As a uniquely precise source of X-rays, synchrotrons allow for imaging 
with resolution orders of magnitude greater than that of conventional imaging modalities, 
potentially allowing for the visualization of cellular morphologies (13). 
Previous research on PCa has been conducted at the Canadian Light Source Inc. (CLS), 
Canada’s first and only synchrotron. Excised prostates have been imaged on the Biomedical 
Imaging and Therapy (BMIT) – Bend Magnet (BM) beamline, with a resolution of 17 
micrometers (14). The positive results of this initial research lead to the goal of imaging in situ 
prostates on the BMIT-Insertion Device (BMIT-ID) beamline. Due to the nature of the research, 
dogs were selected as models for human PCa. Human and canine prostates have similar 
morphologies, biological behavior, and both species spontaneously develop prostate cancer 
contributing to the advantage of the dog model (15). 
 
1.2 Specific Objective 
The specific objective of this research was to design, develop and implement a canine 
positioning system for the BMIT-ID beamline, capable of imaging in situ dog prostates in both 
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cadaver and live dogs. This design was developed based on specific performance specifications, 
some of which included vertical positioning of the dog for imaging, proper restraint of the dog 
and anesthetic equipment capabilities. Through this thesis the design and implementation of the 
canine positioning system is evaluated. The University of Saskatchewan Animal Research Ethics 
Board, operating in accordance with the guidelines set out by the Canadian Council on Animal 
Care, has reviewed and approved the use of live animal subjects and animal tissues for the 
purposes of this thesis. Chapter 2 examines the current understanding of human and canine 
prostate anatomy and pathology, as well provided justification for the use of dogs as a model for 
human PCa. In chapter 3 the general concepts of radiology and synchrotron imaging is discussed, 
and background is provided on the use of PC-CT for in situ imaging.  
Chapter 4 presents the design process for the canine positioning device, along with the 
background information of the detectors used for PC-CT. In chapter 5 the implementation of the 
device is discussed, including cadaver and live dog imaging. Chapter 6 covers the conclusion of 
this thesis. 
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Chapter 2: Literature Review 
This chapter overviews both human and canine prostatic anatomy and pathology, with the 
goal of identifying and discussing similarities and differences between the two species. The 
general morphology and histology of the human prostate is examined first, then an examination 
of several common human prostatic pathologies, including PCa, followed by a review of the 
diagnosis of human PCa. The second half of this chapter focuses on canine prostate anatomy and 
pathology, canine PCa and diagnosis, and directly compares and contrasts human PCa against 
canine PCa. The canine model for human prostatic disease concludes this chapter and justifies 
why dogs were chosen to study human PCa, 
 
2.1 Human Prostate Anatomy 
The prostate is an accessory sex gland of the male genitourinary system that produces and 
secretes components of the seminal plasma. It is believed that prostatic secretions are important 
for spermatozoa survival in the female reproductive tract, though the exact role and function of 
prostatic fluid are poorly understood (3). 
The prostate gland is enclosed by a capsule, approximately 0.5mm in thickness. The 
capsule is composed primarily of collagen, elastin and smooth muscle. The bulk of the glandular 
prostatic tissue is situated posteriorly and bilaterally in the prostate. A fibromuscular stroma 
composes the anterior third of the prostate. The urethra runs the length of the prostate; 
approximately 3cm in length. The urethra is lined by transitional epithelium, and is situated 
closer to the anterior surface of the prostate. The urethra is divided into proximal (preprostatic) 
and distal (prostatic) segments. At the neck of the bladder, circular detrusor muscle fibers project 
distally around the preprostatic urethra, forming the internal urethra sphincter. The seminal 
vesicles and vasa deferentia enter through the prostate parallel and posterior to the postprostatic 
urethra to form the ejaculatory ducts (16), (17). 
 There are four distinct regions and a fibromuscular compartment recognized within the 
human prostate (Figure 2.1). These areas differ in their respected patterning of acini, as well as 
their susceptibility to disease. The four regions of the human prostate are the peripheral, the 
central, the transitional, and the periurethral zones. The peripheral zone of the prostate contains 
approximately 75% of the prostates glandular elements, and occupies most of the posterior and 
lateral aspect of the gland. In the normal prostate, the central zone contains approximately 25% 
of the glandular elements and is located circumferentially around the openings of the ejaculatory 
ducts. Approximately 5-10% of glandular elements are found in the transitional zone of the 
prostate. A thin fibromuscular band separates the transitional zone from other prostatic zones. 
Finally, approximately 1% of glandular elements compose the periurethral glands. Scattered 
along the proximal length of the urethra, the small periurethral glands are enclosed between 
fibers of longitudinal smooth muscle, and are contained within the preprostatic sphincter (17). 
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Figure 2.1: The four glandular zones of the prostate, and the anterior fibromuscular zone. The 
ejaculatory ducts are shown here as well (18). Reprinted with permission. 
 
Approximately 70% of the volume of the prostate is composed of secretory glands, with 
the fibromuscular stroma composing the remaining 30% (16). These secretory glands are 
tubuloalveolar, extending from the capsule of the prostate and emptying into the urethra. The 
secretory glands have simple branching patterns with the main ducts surrounded by acini. The 
acini and ducts are lined by simple cuboidal or columnar epithelium containing abundant 
secretory granules. Between the secretory epithelium and basement membrane are small 
flattened basal cells, forming a nearly continuous layer. Neuroendocrine cells are also scattered 
throughout the epithelium of the ducts and acini, though their exact function and origin remain 
obscure. The stroma of the prostate is primarily composed of fibrillar collagen, elastin, and 
smooth muscle. The secretory cells of the ducts and acini have large, irregular nuclei. The 
luminal surface of the ducts and acini is also irregular, with frequent secretory cells projecting 
into the lumen (19). 
 
2.2 Human Prostate Disease 
Adenocarcinoma accounts for 95% of all diagnosed PCa cases (3). Adenocarcinoma of 
the prostate arises from gland cells and is usually multifocal, i.e. there are multiple sites of tumor 
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growth located throughout the prostate (3).  Benign prostatic hyperplasia (BPH) is a common 
non-cancerous enlargement of the prostate caused by an increase in the number (hyperplasia) and 
size of cells (hypertrophy) (20). Almost 90% of men will have experienced some BPH 
occurrence by the time they reach their 80’s (20). There are also two precancerous conditions 
that can develop within the prostate: prostatic intraepithelial neoplasia (PIN), and proliferative 
inflammatory atrophy (PIA) (3), (21). 
 
2.2.1 Adenocarcinoma 
Most adenocarcinomas are located in the peripheral zone of the prostate, the largest of the 
three zones of the prostate (17). Adenocarcinomas are cancers of glandular epithelial cells. There 
are other rarer types of prostate cancers including, transitional cell carcinoma, sarcoma of the 
prostate, small cell carcinoma, ductal carcinoma, mucinous carcinoma, large duct carcinoma, 
basal cell, and primary lymphoma of the prostate (3). A sarcoma is a cancer originating in 
connective tissue, while a lymphoma is a cancer of lymphatic tissue. Cancers originating 
elsewhere in the body, such as stomach cancer can also metastasize to the prostate (22). 
Adenocarcinoma is diagnosed via histology, and the Gleason classification system is used to 
grade the progression of disease (3). It is used to describe the aggressiveness of PCa, as well as 
the likelihood of metastasis of the cancer. The Gleason system is based on five histological and 
architectural patterns of tumor growth, most notably centered on the changes of the gland cells. 
The Gleason system is used to reflect the differences between normal prostate tissue and 
cancerous tissue. To determine the Gleason score, a biopsy of the prostate must be performed 
(3). 
 
2.2.2 Benign Prostatic Hyperplasia 
Growth in the prostate due to BPH occurs in the transition zone of the prostate, unlike 
adenocarcinoma (8). As men age the prostate naturally develops hyperplasia due to both an 
increase in stromal tissue and epithelial cell number and size, with almost all men in their 70’s 
experiencing some degree of prostatic enlargement (3), (8). BPH presents no early signs and 
symptoms; clinical manifestations only appear when the enlarged prostate begins to press on the 
urethra.  The latter leads to changes in bladder habits (8). Pressure on the urethra from prostatic 
growth manifests as changes in bladder habits, notably frequent urination, which can progress to 
difficulty urinating and painful urination as BPH progresses (23). Symptoms of BPH can be 
treated non-surgically with Alpha-Blockers, which induce smooth muscle relaxation of the 
prostate, bladder neck and urethra, increasing urine flow through the urethra (24). When 
symptoms become severe enough, and medication is no longer a viable treatment option, a 
transurethral resection of the prostate (TURP) is usually performed. TURP is the invasive 
surgical removal of tissue from the area surrounding the prostatic urethra to reduce prostate size 
and decrease prostatic invasion of the urethra. A specialized tube is inserted through the urethra 
to the prostate, and excess prostatic tissue, including the epithelial cells surrounding the urethra 
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are ablated, increasing the size of the constricted urethra. This procedure may have to be 
repeated again several years after the initial surgery if symptoms return due to subsequent 
prostatic hyperplasia (8).  
 
2.2.3 Prostatic Intraepithelial Neoplasia 
Prostatic intraepithelial neoplasia (PIN) is a multifocal, multi–grade condition that arises 
from the epithelial cells that line the ducts and the acini inside the prostate. There are two grades 
of PIN, low-grade PIN (LGPIN) and high-grade PIN (HGPIN). HGPIN occurs when the nucleus 
of epithelial cells become enlarged, and increased cellular proliferation causes the ducts to fill 
with excess epithelial cells. LGPIN shows similar cytological changes to HGPIN, and is 
regarded as a part of the spectrum of changes seen in benign prostatic tissue, though not as 
clearly pronounced. LGPIN show tufted crowding, stratification and irregular spacing of luminal 
cells, but without a large increase in nucleoli seen in HGPIN (25), (26). HGPIN is easily 
identified with a biopsy and histological evaluation due to the increased nucleoli located within 
duct structures throughout the prostate. HGPIN shares many similar characteristics to PCa, 
including cytological changes, increased incidence with age, and increased occurrence in the 
peripheral zone. Unlike PCa however, HGPIN does not increase serum Prostate-Specific Antigen 
(PSA) levels (21), (27). Recent studies have shown that men with HGPIN had an increased risk 
of PCa diagnosis during a secondary follow-up biopsy, as compared with men whose initial tests 
revealed only LGPIN (3), (8), (21), (25).  Due to poor interobservation between pathologists and 
a clear link to PCa, LGPIN is not seen as a diagnostically useful pathological observation (28). 
 
2.2.4 Proliferative Inflammatory Atrophy 
In humans as well as dogs, Proliferative Inflammatory Atrophy (PIA) is suspected of 
being a precursor to PCa (27). Inflammation of the prostate caused by pathogens or pro-
inflammatory cytotoxic agents cause proliferation of prostatic glandular cells. The damage, 
inflammation, and subsequent regeneration of glandular cells is thought to induce PCa 
generation (29). This proliferation of glandular cells leads to the appearance of nuclear disorder, 
large nuclei and nucleoli within glandular cells. These areas of dysplasia are associated with both 
chronic inflammation and epithelial cell proliferation, and are usually found adjacent to HGPIN 
and PCa (30). Genetic material in the epithelial cell may become damaged due to the release of 
reactive oxygen species during chronic inflammation, which might lead to PIN, and eventually 
adenocarcinoma (18), (30). 
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2.3 Diagnosis of Prostate Cancer in Humans 
2.3.1 Digital Rectal Examination 
A digital rectal examination (DRE) may be used by a physician to palpate the prostate to 
determine if there are any structural abnormalities. A gloved finger is inserted into the rectum of 
the patient and the peripheral zone of the prostate is palpated. The examiner assesses the size, 
symmetry, shape and consistency of the posterior surface of the prostate. Abnormalities of the 
prostate felt during DRE include nodularity, induration and asymmetry. Small tumors or those 
near the anterior surface of the prostate may go unnoticed during DRE. The tenderness and 
presence and consistency of any nodules is also assessed. The normal prostate is free of nodules 
with a palpable median sulcus separating the lateral lobes. A DRE test is often performed as part 
of a general annual checkup for men over the age of 50, or earlier for men who have a family 
history of prostate cancer (1). If abnormalities are felt, more tests are recommended for the 
patient, usually a prostate specific antigen (PSA) test (1). The prostatic volume can also be 
estimated during DRE, though it is usually underestimated (30). 
 
2.3.2 Prostate Specific Antigen 
Prostate specific antigen is a protein synthesized by the epithelial cells of the prostate 
gland and is found in the serum of healthy men (3). The PSA test is a measurement of the blood 
PSA level, and was first used as a monitor for PCa treatment response and recurrence in the early 
1980’s. During PCa treatment, the level of PSA in the blood plasma can be used to gauge how 
effective the treatment was; a decreasing PSA level indicated a positive treatment response. If, 
post-treatment, the PSA levels began to rise, physicians interpreted this as a sign that there was a 
recurrence of PCa (31). In the 1990’s the test was approved by the United States Food and Drug 
Administration as a screening aid for PCa diagnosis (32). The PSA molecule is normally found 
in the blood at very low levels, <4ng/mL, with serum PSA levels between 4-10ng/ml potentially 
indicating PCa (3), although approximately 66% of men with elevated PSA levels do not have 
PCa (25). Other prostatic diseases, such as prostatitis and BPH, may cause elevations of PSA 
levels, and could potentially cause false-positive test results (32). Although most incidences of 
PCa increase serum PSA levels, approximately 20% of men with clinically significant PCa will 
have normal PSA serum levels (33). Therefore, the use of PSA tests for PCa screening has been 
controversial for many years. In Canada, there were two peak yearly incidence rates of PCa 
following intensified screening activity using the PSA test in 1993 and 2001 (3). The Canadian 
Task Force on Preventative Health Care recommended that PSA not be used to screen men for 
PCa, as they found that the certainty of harm outweighed the potential benefits (33). One of the 
major factors in the taskforce’s decision was both the inability of the PSA test to distinguish 
between benign and malignant cancer, as well as the between low-grade and high-grade cancers. 
Due to the PSA test’s inability to accurately predict which patients with elevated PSA levels 
should undergo further testing, millions of Canadian men needlessly underwent prostate biopsies 
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(34). The results of the European "Randomized Study of Screening for Prostate Cancer" trial 
estimated that the PSA testing as a screening test for PCa led to an overdiagnosis of PCa in 40-
56% of men (33). The task force also found that when using a threshold of 4.0ng/mL, the false 
positive rate was 19.8% in men screened for PCa using PSA levels. Men with false-positive test 
results were usually invited to undergo further invasive testing, potentially having multiple 
needle biopsies. Biopsy of the prostate carries with it multiple risk factors, including hematuria, 
infection, hospital admission and death (7), (33). 
 
2.3.3 Transrectal Ultrasound 
A transrectal ultrasound (TRUS) test may be performed on males who are experiencing 
symptoms associated with prostate disease, have elevated PSA levels, or if abnormalities are felt 
during a DRE. An ultrasound transducer is inserted into the rectum of the patient, and the 
prostate and surrounding tissue are displayed on the ultrasound monitor. A TRUS test is used to 
visualize the size of the prostate, as well as to see if there are any structural abnormalities. TRUS 
may also be used to guide a biopsy needle to collect samples from abnormal areas of the prostate 
(3), (35). 
 
2.3.4 Needle Biopsy 
A biopsy of the prostate is required to accurately diagnose PCa. A prostate biopsy may be 
performed if abnormalities were felt during a DRE or seen with TRUS (3), (7). A biopsy may 
also be performed if high levels of PSA are detected; but there have been recent 
recommendations to move away from this practice, see section 2.3.2 (33). During a prostate 
biopsy, tissue samples are taken from multiple sites; usually 6-12 locations (27). Approximately 
20-24% of needle biopsies result in false negatives, as abnormal areas may be overlooked, 
missed or under sampled (3), (21), (27). A false negative result is a term used to describe a 
situation in which a diagnostic test, such as needle biopsies, showed a negative or normal result, 
when in fact the patient had a positive test result. During a transrectal biopsy a specialized biopsy 
needle is inserted into the rectum and passes through the wall of the rectum into the prostate 
where tissue samples are collected. Transrectal ultrasound is usually used to visualize the 
location of the prostate and guide the needle during sample collection. Potential side effects of 
the biopsy include pain, infection, and bleeding (7). The results of a prostate biopsy are used to 
determine whether PCa is present or not, and if cancer is present, to describe the type and 
aggressiveness of the cancer using the Gleason classification system (3).  
 
2.3.5 Histopathology of Prostate Cancer 
Several microscopic features form the basis for the histopathological diagnosis of PCa. 
There are both primary and secondary criteria for diagnosis, with no specific feature being 
indicative of PCa, except for perineural invasion (36). Perineural invasion is the presence of 
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malignant adenocarcinoma glands in the perineural space, i.e. the periphery of cells surrounding 
the nerves passing through and innervating the prostate. The primary criteria refer to the pattern 
or architecture of the glands. Normal prostatic glands are arranged in lobules, and are medium in 
size. Malignant glands are found to be typically small, forming microacini, arranged 
haphazardly, overcrowded, have lost their lobule formation, are fused together, and have invaded 
between benign glands (36). The secondary features of PCa are cytological, and include the 
presence of hyperchromatic nuclei, the absence of the basal cell layer, and glands crowded with 
cells. The grading of PCa is based on the deviation of malignant glands from normal histological 
morphology, with the Gleason grading system being the internationally accepted standard. In 
2005, the Gleason classification system was updated to better accommodate current diagnostic 
practices through the International Society of Urological Pathology (ISUP) Consensus 
Conference (37). In 2013 a new system of PCa grading was proposed, consisting of five grade 
groups, with group five indicating the least favorable prognosis and group one the most. This 
proposed five group grading system is in contrast to the Gleason system, where there are 25 
potential grading combinations. The new PCa grading system was validated with a retrospective 
study of 25000 men between 2005 and 2014 who received PCa treatment either with radical 
prostatectomy or radiotherapy. The study concluded that the contemporary PCa grading system 
has several benefits over the Gleason system including: simplified grading, improved 
stratification between grades, and potential reduction in PCa overdiagnosis (38).  
 
2.4 Canine Prostate Anatomy 
The prostate gland of dogs sits at the caudal neck of the bladder with the urethra 
traversing through it (39), (40). The gland is bound ventrally by the symphysis pubis and ventral 
abdominal wall, and dorsally by the rectum. The dorsal and ventral portions of the prostate are 
separated by the two folded layers of the peritoneum bounding the rectogential space. The 
urethra passes through the dorsal center of the prostate gland. Contrary to the human prostate, the 
canine prostate is not divided into zones (41). A median septum divides the canine prostate gland 
into left and right lobes. The left and right lobes are further divided into lobules by capsular 
trabeculae. Each lobule consists of many compound tubuloalveolar glands. The tubuloalveolar 
glands are lined by columnar epithelium, similar to in the human prostatic gland. The ducts from 
the tubuloalveolar glands empty into the urethra (39). The size of the prostate gland varies with 
the age and weight of the dog (42), (43). 
The prostate gland is located in the caudal abdomen or pelvic cavity depending on the 
size and age of the dog. In dogs less than two months of age the prostate gland is typically found 
in the abdominal cavity, before the urachal vestige breaks down allowing the prostate to move 
caudally into the pelvic cavity. During puberty, around 5-8 months of age, the prostate gland 
begins to enlarge and the gland starts to move cranially back toward the pelvic brim. By four 
years of age hyperplastic enlargement of the prostate results in a further shift of the gland 
cranially into the abdominal cavity; at this age the prostate typically is located equally within the 
   10 
abdominal and pelvic cavities. Usually by ten years of age in an intact dog the entire prostate 
gland has shifted into the abdominal cavity (41). 
As in humans, the exact function of the canine prostate gland is not entirely understood. The 
canine prostate gland secretes citrate, lactate, cholesterol, and enzymes. It is commonly believed 
that the glandular secretions help to create an optimum environment for sperm survival within 
the female reproductive tract (39) 
 
 
Figure 2.2: The gross anatomy of the canine prostate. 
 
2.5 Canine Prostate Disease 
2.5.1 Prostatic Neoplasia 
There are two major types of prostatic neoplasia diagnosed in dogs, adenocarcinoma and 
transitional cell carcinoma, with adenocarcinoma more commonly diagnosed than transitional 
cell carcinoma (42). Transitional cell carcinoma originates from urethral cells, while 
adenocarcinoma originates from glandular cells within the prostate (44). Immunohistochemistry 
of specific prostate cellular markers are needed to distinguish adenocarcinoma from transitional 
cell carcinoma (42). There are a large range of cellular markers used to differentiate the two 
types of neoplasia, with PSA being a primary marker between high-grade transitional cell 
carcinoma and adenocarcinoma (45).  Prostatic neoplasia is usually not diagnosed until clinical 
signs of the disease are present, frequently with local or regional metastasis occurrence. 
Adenocarcinoma of the prostate is usually diagnosed in 8-10-year-old dogs, with a much lower 
incidence rate in younger dogs (46). Castration does not appear to affect the prevalence of 
prostate neoplasia, as castrated and intact dogs have the similar occurrence rates of the disease 
(39), (47). Clinical signs of prostatic neoplasia include anorexia, weight loss, stranguria, 
hematuria, tenesmus, and weakness of the rear limbs (47). As in humans, metastases occur to 
regional lymph nodes and the pelvic bone (39). Through transrectal examinations, the prostate of 
affected dogs is typically revealed to be irregular, enlarged and asymmetrical (42), (47). Canine 
Prostate Gland 
Ductus Deferens 
Ductus Deferens 
Urinary Bladder 
Urethra 
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adenocarcinoma mimics human PCa in heterogeneity, increased prevalence in older patients, 
histopathology of disease and association with skeletal metastasis (48). The incidence of 
adenocarcinoma in humans and canines similarly increases with age (48), (49). The median age 
of adenocarcinoma in dogs is 10 years, which is approximately equivalent to the average age of 
diagnosis in human men, 70 years, when converted to human years (49). Human and canine PCa 
may metastasis to bones, causing osteoblastic lesions in both species (50), (51), (52). 
 
2.5.2 Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 
As in humans, the canine prostate gland increases in size with age, with 95% of all intact dogs 
affected by the age of 9 (47). One study found that 50% of beagle dogs in their cohort developed 
BPH by the age of 5, suggesting a difference of incidence between species (53). The canine 
model of BPH is currently the only model for human BPH, with sufficient similarities between 
the pathology and anatomy of both species to consider it a reliable comparison (54), (55), (56). 
The incidence of BPH is also age related in both species, similar to PCa (53). One of the only 
differences in pathophysiology of BPH between the species is that the human disease is 
characterized by hyperplasia of the stromal cells within the periurethral space, whereas in canine 
BPH there is diffuse epithelial or glandular proliferation throughout the entire prostate (49), (54). 
Most cases of canine BPH do not show clinical signs, but occasionally the enlargement can cause 
hematuria or tenesmus, as well as urethral discharge, hemospermia, or a silted gait (42), (47). 
Definitive diagnosis of BPH in dogs can only be made with a needle biopsy, though a 
presumptive diagnosis is often made based on history, DRE, and/or ultrasonographic appearance 
of the prostate gland. Castration is the most effective treatment, causing a 70% reduction in 
prostate size following surgery, with completed involution taking up to four months (42). 
 
2.5.3 Prostatic Intraepithelial Neoplasia 
Similar to humans, canine prostatic intraepithelial neoplasia (PIN) is an atypical epithelial 
lesion of the prostate considered to be a precursor of prostate cancer (52), (30). PIN is a 
multifocal, multi–grade condition that arises from the epithelial cells that line the ducts and the 
acini inside the prostate. High grade PIN (HGPIN) is considered to precede PCa in both dogs and 
humans (57), (58). Histologically, canine HGPIN is similar to human HGPIN, with proliferation 
of the luminal secretory cells lining pre-existing ducts, and characteristic cytological changes and 
abnormalities including nuclear crowding, variation in nuclear size and enlargement of nucleoli 
(59), (60). The disruption of the basal cell layer, increase in proliferative index and increase in 
micro-vessel density characterize both human and canine HGPIN (60). The prevalence of 
HGPIN in dogs seems to be influenced by sexual status with one study reporting HGPIN in 55% 
of intact dogs compared to only 9% in castrated dogs (57), (58). 
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2.5.4 Proliferative Inflammatory Atrophy 
Canine and human proliferative inflammatory atrophy (PIA) share many characteristic 
histological features, including: discrete foci of hyperchromic glands, acini glands having two 
layers of epithelial cells with the luminal layer of cells appearing as attenuated cuboidal cells, 
and atrophic acini glands appearing to have only one layer of attenuated epithelial cells (61), 
(60). PIA is seen as a preneoplasitc lesion in both humans and dogs (60). The proposed method 
of carcinogenesis involves a chronic cycle of tissue damage and regeneration, with prolonged 
reactive oxygen species exposure causing oncogenic changes to the cellular DNA (27), (61). 
Several studies have found evidence of PIA in canine prostates, suggesting it is not an 
uncommon disorder, and may be reasonably well detected with routine biopsy (61).  
 
2.6 Diagnosis of Prostate Cancer in Canines 
2.6.1 Prostate Specific Antigen & Canine Prostate Specific Esterase 
In humans, serum prostate specific antigen (PSA) levels can be a useful screening tool for 
facilitating PCa diagnosis (33).  PSA is a proteolytic glycoprotein found in normal, hyperplastic 
and malignant human prostatic tissue, and can be found in similar canine prostatic tissue using 
immunohistochemical techniques (62). Though detectable in human serum, PSA is not 
detectable in canine serum, and therefore its use as a screening tool for canine PCa is not 
recommended (62), (63). Canine prostatic tissue secretes an enzyme called canine prostate 
specific esterase (CPSE), a proteolytic glycoprotein similar to PSA, though different in their 
respective enzymatic activity and substrate binding (62).  Both PSA and CPSE are under 
hormonal regulation, with decreases in serum testosterone levels resulting in decreases in serum 
SPA and CPSE levels, while increasing levels of testosterone increases the levels (63). CPSE has 
been identified in normal, hyperplastic, and malignant canine prostatic tissue, similar to PSA in 
humans (62). Bell et al. (1995) found the mean serum CPSE concentrations were higher for dogs 
with BPH, but found no statistically significant difference between healthy dogs and those with 
PCa (62). Neither PSA or CPSE are considered useful screening tool for PCa diagnosis in dogs.  
 
2.6.2 Digital Rectal Examination 
A physical examination, called a digital rectal examination (DRE), of the canine prostate is a 
basic non-invasive screening test for prostate abnormalities such as BPH and PCA (64). The 
veterinarian inserts a gloved finger into the rectum of the dog while applying pressure to the 
abdomen and palpates the prostate.  The normal canine prostate should have a smooth surface, 
solid consistency free of nodules, be isothermic and not cause pain to the dog during palpation 
(63). The symmetry of the prostate gland is evaluated during a DRE, using the central sulcus on 
the dorsal surface of the gland to determine the bilateral symmetry of the prostate. The left and 
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right lobules of the prostate in a normal canine prostate are similar in size. If abnormalities are 
felt during a DRE, the veterinarian should investigate further (63). 
 
2.6.3 Transabdominal Ultrasound 
Transabdominal ultrasound (TAUS) is used for visualizing the internal architecture, external 
texture and structural features within the prostate. Similar to humans, ultrasonography is used for 
performing percutaneous or aspiration biopsy of the canine prostate. The length, width and depth 
of the prostate gland can be determined using TAUS, allowing for a volume estimate to be made 
(65). If abnormalities are suspected, such as BPH or PCa, the volume of the prostate can be 
monitored overtime for any change. The prostate is normally displayed with a homogenous 
pattern during TAUS, but an inflamed, hyperplastic or neoplastic prostate loses this homogenous 
pattern (66). TAUS has been successfully used to establish a preliminary diagnosis, and is 
routinely used as a screening tool for prostatic disease (67).  
 
2.6.4 Fine Needle Aspiration & Prostatic Biopsy 
Fine needle aspiration (FNA) is a minimally invasive procedure to collect prostatic tissue for 
bacterial cultivation and/or cytology. TAUS may be used to enhance the effects of FNA by 
allowing for better targeting of questionable tissue (68). The prostate gland can be approached 
and sampled through the perineum, caudal abdomen, perirectum and rectum (63), (42). As in 
humans a specialized needle is inserted into the prostate and tissue samples are collected. The 
reliability of FNA in PCa diagnosis is approximately 80%, but can reach up to 89% (69).  
The gold standard for determining prostatic disease in dogs is a histological evaluation of a 
prostate biopsy (67).  A prostate biopsy is a more invasive diagnostic test compared to FNA 
(63).A prostate biopsy is performed in cases where less invasive diagnostic tests do not render a 
diagnosis, such as TAUS, DRE and/or FNA, or in cases were an immediate diagnosis is needed 
(42). There are two main methods of prostatic biopsy: percutaneous and excisional (i.e. during 
surgery). As in FNA, percutaneous biopsies can be collected through the perineum or 
transabdominally, though the patient is sedated or anesthetized (39). The procedure is most often 
guided by ultrasound, but can be performed blindly if performed tranrectally (67). The samples 
collected can be cultured and evaluated both cytologically and histopathologically for prostatic 
diseases and abnormalities.  
 
2.6.5 Histopathology of Canine Prostate Cancer 
The canine prostate gland is composed of tubuloalveolar structures of glandular components 
surrounded by a smooth muscle and connective tissue stroma (70). The normal epithelial cells of 
the prostate are well defined cuboidal or columnar cells, containing small nucleoli and an oval 
nucleus (71). In intact male dogs the acini are composed of luminal tall columnar and cuboidal 
secretory epithelial cells with a basal cell layer (70). In contrast to humans, the basal cell layer in 
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dogs is discontinuous (71), (30). This lack of the continuous basal cell layer in humans is a 
strong indicator of PCa, yet in dogs is entirely normal, which is a specific histological difference 
between the two species (30), (37). As described previously, the human prostate gland contains 
four regions: the central zone, the peripheral zone, the transitional zone, and small periurethral 
glands (17). Conversely, the canine prostate does not exhibit zonal anatomy, though it contains a 
median septum which separates the prostate into the left and right lobes (72). In humans PCa 
arises primarily in the transitional zone of the prostate, while in dogs there is growing evidence 
to suggest that PCa originates from the ductular epithelium in the periurethral space (72), (73).  
HGPIN and PIA are believed to be precancerous histological changes in both human and canine 
prostates (52).  
 
2.7 Canine Model for Human Prostatic Disease 
Animal models have been used in the past to gain a deeper pathogenic understanding of 
multiple types of cancers, such as lymphoma, soft-tissue sarcoma, osteosarcoma, mammary 
gland carcinoma, and melanoma (15). Dogs represent a unique model to better understand PCa in 
humans, as both share many characteristics and morphologies. For example, dogs are the only 
other mammal besides humans that commonly develops spontaneous PCa and BPH (74), (75), 
(76). As discussed previously, human and canine BPH and HGPIN develop and progress 
similarly, and PIA is believed to be a histological precancerous lesion in both humans and dogs 
as well. There are also parallels between the diagnosis of PCa in each species. Both male humans 
and dogs produce a specific prostate protein detectable in serum, and although PSA and CPSE 
are distinct, they share a remarkable amount of similarities. The gold standard of PCa diagnosis, 
histology of prostate biopsy cores, is also the same between humans and dogs.  There is also a 
similar tendency for PCa to metastasize to the bone in both humans and dogs (74), (75). In 
contrast, a major difference between the two species is the continuity of the basal cell layer 
around the epithelial glandular lining of the prostate. 
Considering these resemblances, dogs can allow us to test and perfect the positioning 
device on the BMIT-ID beamline before modifying it for human imaging in the future. The 
canine positioning device will be used to generate a considerable amount of data on both living 
and cadaver canine prostates. Synchrotron imaging may provide a unique insight into the 
pathophysiology of prostatic diseases in dogs, and can be used to study BPH, HGPIN and PCa 
development. The device will allow for future canine studies to be conducted on the BMIT-ID 
beamline, not just for prostate imaging research. 
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Chapter 3: Medical Imaging & Synchrotron X-ray Source 
3.1 Overview of Conventional Medical Imaging 
A general concept and understanding of X-ray medical imaging is needed to appreciate the 
data collected for this thesis. This chapter overviews X-ray medical imaging, including the 
generation of X-rays using a synchrotron. An introduction on how X-rays are used to generate 
contrast within an object begins Chapter 3, followed by a section on computed tomography and 
phase contrast - computed tomography, as this was the method used to collected in situ canine 
prostate reconstructions.  
 
3.1.1 Introduction to Radiography 
X-ray images are formed via the differential attenuation of the X-rays as they pass through a 
sample. Variation in thickness and density within the sample cause fluctuations in the transmitted 
X-ray intensity. Simply put, the amount of photons entering a sample is greater than the amount 
of photons leaving the sample due to the properties of the sample. According to the Beer-
Lambert law, the ratio of photons passing through a sample to incident sample photons is related 
to the integral of the sample absorption coefficient and the distance the X-ray photons pass 
through the sample, given in the following equation (77). 
 
 
 
Where I0 and I are the incident and transmitted beam intensity, respectively, μ is the linear 
attenuation coefficient, and x is the thickness of the sample. In uniform materials, the attenuation 
of the X-ray beam will be constant throughout the sample.  
 
 
Figure 3.1: The linear attenuation of an X-ray beam I0 by a homogenous object with μ linear 
attenuation coefficient and x thickness. 
 
 
[3.1] 
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For heterogeneous samples, such as human tissue, the equation is modified to (77): 
 
 
 
Where the product of the linear attenuation coefficient and thickness of each separate object 
are added together.  
 
 
Figure 3.2: The linear attenuation of an X-ray beam I0by a heterogeneous object with different 
linear attenuation coefficients µ1 and µ2and thicknesses x1 and x2.  
 
The linear attenuation coefficient of objects is energy dependent. This means each 
specific wavelength of photons passing through the sample will be attenuated by a different 
amount. As a general rule, the higher the X-ray photon energy, the lower the linear attenuation 
coefficient, meaning higher energy photons pass through materials preferentially, compared to 
lower energy photons. Due to the smaller absorption of high energy X-rays, the dose received 
during imaging is smaller compared to low energy X-ray photons. The linear attenuation 
coefficient can be described by two material properties: the linear attenuation coefficient (µ), and 
the density of the material (ρo). The mass attenuation coefficient (µ/ρo) of the material is more 
commonly found than the linear attenuation coefficient in the literature due to the mass 
attenuation coefficients ability to normalize same materials of different density, e.g. liquid versus 
ice water (78). 
 
 
Contrast of objects embedded in a background material is defined as how much the object 
signal is detectable from the background signal. Contrast can also be described as the difference 
of pixel value in the image between an area of interest and the surrounding background. The 
contrast of an image depends on the characteristics of the material being imaged, as well as the 
o
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general setup of any imaging process. Contrast can be further broken down and described as 
radiographic versus detector contrast for X-ray imaging. Detector contrast refers to the ability of 
the detector system to measure and convert photon count differences across the X-ray beam into 
an electronic signals representing the image. Radiographic contrast refers to the intensity I of the 
X-ray beam passing through different regions of the object being scanned. Radiographic contrast 
depends on a number of different physical properties of the material including atomic number, 
physical density, electron density, thickness, as well as the energy of the incident photon beam. 
For the purpose of this thesis, contrast will refer to radiographic contrast, as the parameters of 
detector contrast are outside the scope of this thesis. For X-ray radiography, the absorption 
contrast can be examined and explained using an object with μobject linear attenuation coefficient, 
and xobject thickness embedded in matrix with μMatrix linear attenuation coefficient and xmatrix 
thickness, shown in Figure 3.3 (79).  
 
 
Figure 3.3: The linear attenuation of an X-ray beam I0 through a matrix with an object embedded 
inside.  
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The contrast of this embedded object can be determined using the following formula, [4]. 
Inserting equation [1] and [2], the contrast formula becomes [5], which can be simplified to [6]. 
 
 
 
 
 
 
The contrast of an object is given by the absorption differences between the matrix and 
the embedded object, and the object thickness. As previously stated, the absorption of X-rays in 
material is dependent on the mass attenuation coefficient, density, and incident X-ray photon 
energy. Therefore, in samples of near homogeneous mass attenuation coefficient, such as 
cancerous and non-cancerous tissue, contrast relies heavily on density differences (79).  
 
3.1.2 Computed Tomography  
The word tomography comes from the Greek word “tomo”, meaning to cut. Computed 
tomography allows for the viewing of internal structures of an object without cutting the sample 
open. A viable clinical Computed Tomography (CT) scanner was first separately introduced by 
both Sir Godfrey Newbold Hounsfield and Allen McLeod Cormack in 1967. Computed 
Tomographic imaging technology builds on conventional radiology, though CT is not subject to 
the same limitations. In conventional radiography, three-dimensional (3D) objects within a 
sample are superimposed onto a two-dimensional (2D) image, causing confusion and 
interpretation issues for the viewer due to the silhouette effect. Computed tomography images on 
the other hand, provide cross-sectional images of the interior of the sample, enabling 3D 
information to be viewed through multiple 2D images. Digital processing of the consecutive 2D 
images can be performed to allow a 3D image to be constructed. Since its inception, CT has also 
provided high soft tissue contrast, enabling the visualization of different tissues and organs, 
compared to simple radiographs (80).  
 
Tomography is based on the approach that detecting information from multiple angles around 
an object can be reconstructed into a section of the object. CT uses many radiographs taken at 
matrix
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equidistant intervals 180° around an object to produce a section image of the object. The cross-
section geometry of an object can then be visualized from hundreds of radiographs taken at 
slightly different angles, called tomographic projections, by processing using computer 
algorithms (77). This process is discussed in depth later in this section.  
Conventional CT has evolved greatly since its inception in the 1970’s (80). The clinical CT 
setup can be described as consisting of three principle components: The X-ray source, the object 
being imaged, and the X-ray detectors, Figure 3.4. The source and detector in conventional CT 
machines rotate on a gantry around the object being imaged, e.g. a human. The rotation of the X-
ray source and detector allow for a 180° scan that collects contiguous tomographs of the subject 
being imaged. Conventional CT machines employ a cone beam projection X-ray source, which is 
contrary to a synchrotron X-ray source, which employs parallel beam projections, discussed 
further in the thesis. 
 
 
Figure 3.4: Internal components of a clinical CT machine, where T is the X-ray source, D is the 
X-ray detector, X is the cone path of the X-ray beam, and R is the rotation (clockwise) direction 
of the gantry (81). Reprinted with permission. 
 
To discuss the tomographic reconstruction process, parallel beam geometry will be used. Each 
tomographic projection is the line integral representation of the total attenuation of the object at 
that particular angle. A line integral is the integral taken along the line of a function with a 
continuously varying value, such as the linear attenuation coefficient at each point in a sample 
being imaged with X-rays. Each row of pixels of a tomographic projection can be expressed as a 
function with respect to each of the pixel value and location (82).  
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Figure 3.5: A visual aid to describe the collection of parallel beam tomographic projections 
where the source and detector rotate around the homogeneous sample. The transmitted beam 
intensity versus distance graphs in the figure show continuous lines of each pixel’s line integral, 
i.e. the absorption of the X-ray beam path. Each function shows the total attenuation of the 
sample at two specific angles 90° to each other.  
 
The final pixel value of the line integral is the summation of all the absorption occurring 
on the line through which the photons passed. In digital medical imaging, this value is expressed 
as a grey pixel value. The 2D representation of this can be seen as a typical radiograph, or in this 
case, a tomographic projection as seen in Figure 3.5. Following collection of the projection 
tomographs, computer algorithms are then used to reconstruct a sample slice from each of the 
line integrals (83).  
There are several different computational methods to reconstruct the 2D sample slice from the 
series of tomographic projections. The following will briefly describe the Filtered 
Backprojection method, as this was the method used to reconstruct the data collected for this 
thesis. The method of Backprojection involves setting the projected tomograph pixel values 
equal to the ray lines along the path the tomograph was taken on. A backprojected image is 
formed by “smearing” the projections, also called views, back along the direction they were 
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originally acquired on. The final reconstructed image is the sum of all the backprojected views. 
Unfortunately, this leads to blurring of objects and sample, as seen in Figure 3.6 (83). 
 
 
Figure 3.6: Backprojection method of CT reconstruction. The image (a) is generated by taking 
each tomographic projection (view) and “smearing” it along the path it was acquired on. (a) The 
reconstructed image is generated from three views;(b) The reconstructed image is generated 
using many views, blurring of the object is apparent (83). Reprinted with permission. 
 
A single point within the real object being imaged is reconstructed as a circular ring of 
decreasing radial intensity, seen as a circularly symmetrical spread function decreasing with the 
reciprocal of the radius. Fortunately, this blurring effect can be overcome with filtering. This is 
called Filtered Backprojection, and is one of the most common tomographic reconstruction 
methods.  In filtered Backprojection, each tomographic projection is convolved with a 1D filter 
kernel, creating a set of “filtered” projections. This means the function of transmitted beam 
intensity is multiplied by another function called the filter function. This convolving of the two 
functions creates new projection tomographs, called filtered projections or views. The filtered 
projections are then backprojected, i.e. smeared, as described above, creating a filtered 
reconstructed image. These filtered projections supply a closer reconstruction approximation to 
the real object being imaged compared to the unfiltered projections (83).  
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Figure 3.7: Filtered Backprojection method of CT reconstruction. The image is generated by 
taking each filtered tomographic projection (view) and “smearing” it along the path it was 
acquired on. a) The filtered reconstructed image is generated from three filtered views; b) The 
filtered reconstructed image is generated using many filtered views. Object blurring was 
removed with filtering (83). Reprinted with permission. 
 
In fact, with an infinite number of projections taken of an object, the filtered 
Backprojection method can reconstruct the image perfectly. However, in a practical sense this is 
impossible, and therefore the reconstruction is just a very close approximation of the actual 
object. Each reconstructed slice is one row of the detector’s pixels, e.g. if the detector has a pixel 
array of 1000 x 200, up to 200 slices of the object could be reconstructed from a single scan. 
 
3.2 Synchrotron X-ray Source  
The Canadian Light Source Inc, located in Saskatoon, Saskatchewan was utilized as the X-ray 
source for the data collected in this thesis with the Biomedical Imaging and Therapy – Insertion 
Device Beamline (BMIT-ID) used to collect the data.  
Synchrotron radiation is produced by accelerating relativistic electrons through bending 
magnets, superconducting wigglers or undulators (84). Wigglers and undulators are devices 
primarily composed of a series of alternating magnetic poles, which force an electron beam 
passing through them to conform to a characteristic sinusoidal trajectory. Electrons are produced 
by a linear accelerator and injected into a booster ring, which accelerates the electrons to near the 
speed of light, referred to as relativistic speeds. After the electrons gain relativistic speed, they 
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are injected into a storage ring. The electrons travel in a near circular path inside the storage ring, 
which consists of straight sections and bends. The bending of the electron path is done using 
high-powered bending magnets. There are 24 bending magnets at the CLS, each altering the 
trajectory of the electrons by 15° in the transverse plane of the electron movement (85). As the 
relativistic electrons pass through the bending magnets, the magnetic field accelerates the 
electrons, forcing them to change direction, and causing them to emit electromagnetic radiation. 
The relativistic speed of the electrons causes this emitted radiation to be seen as hard 
polychromatic X-rays from a laboratory reference frame (12). 
There are several insertion devices found within the straight sections of the storage ring at the 
CLS. These insertion devices incorporate a series of oppositely oriented magnetic poles. The 
electron beam passing though the insertion device is accelerated by the magnetic fields, causing 
the electrons to undulate in a sinusoidal fashion. The sinusoidal path of the electrons passing 
through the insertion devices produces polychromatic electromagnetic radiation. The 
polychromatic electromagnetic radiation, including hard X-rays, generated from either an 
insertion device or bending magnet are highly collimated in the transverse direction of the 
electron beam, and travel in tangent lines away from the storage ring. Specialized beamlines, 
tangent to the storage ring, house the radiation as it leaves the storage ring and travel to the 
imaging hutches at the end of the beamlines (1). 
BMIT has two beamlines for x-ray imaging, the insertion device (ID) beamline, and the 
bending magnet (BM) beamline. They are named after the device used in the storage ring to 
produce X-rays. A 4.3 max Tesla (T) superconducting wiggler is the source of X-rays on the ID 
beamline. BMIT-ID’s superconducting wiggler has 25 full-field magnetic poles, as well as 2 
half-field magnetic poles, causing the electron beam to “wiggle” inside the device in a sinusoidal 
shape as the electrons pass through it. The periodicity of the electron beam is 4.8 cm, with a 
magnetic deflection parameter K of 19.3. The BMIT-ID superconducting wiggler supplies a 
critical photon energy of 24 keV, at a maximum magnetic field of 4.3 T (86). The polychromatic 
X-rays generated by the superconducting wiggler travel down the beamline and into a 
specialized primary optics enclosure (POE-3) hutch, where the incident polychromatic X-ray 
photons are refined (1). Specific X-ray beam energies are selected from the polychromatic source 
using a monochromator, which is a series of two perfect silicon crystals refracting the incident 
X-ray beam at specific angles. The monochromator utilizes Bragg’s law of crystal refraction to 
select a specific wavelength (in reality a bandwidth 
∆𝜆
𝜆
) of photons passing through it (87). In this 
way a monochromator can be tuned to allow only a specific wavelength through. After the 
monochromator has selected a specific bandwidth, the monochromatic X-rays can be filtered 
using different thickness of specific metals, e.g. copper. The refined X-rays then enter the 
imaging hutch, pass through the sample, and are collected with an X-ray detector. The size of the 
beam at the sample location in the imaging hutch is approximately 200 mm x 11 mm. The 
imaging stage rotates in a single plane parallel to the ceiling and floor of the imaging hutch. The 
imaging axis is therefore perpendicular to this plane, and parallel to the walls of the hutch as 
shown in Figure 3.8.  
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Figure 3.8: The experimental setup of the BMIT imaging hutch. The X-ray beam is indicated 
with a blue arrow. The imaging axis is indicated with a red arrow, notice how it is 
perpendicular to the imaging beam path. The detector is indicated with a green arrow. 
Modified from (1). Reprinted with permission. 
 
3.3 Phase Contrast – Computed Tomography 
Phase contrast imaging (PCI) is an imaging technique that allows for the phase 
information of X-rays passing through a sample to be collected. Especially useful for soft tissue 
imaging, PCI is more sensitive to density variations compared to absorption X-ray imaging (88). 
PCI’s improved soft tissue contrast results from the phase cross section of low Z materials being 
1000x that of the absorption cross section, indicating PCI is more sensitive than absorption X-ray 
imaging (11). The cross section refers to the probability of an absorption or scattering process 
occurring in an area due to elastic scattering, inelastic scattering, and photoelectric absorption 
(89). Elastic scattering refers to the conservation of kinetic energy of the photon after a 
modification to the direction of propagation, in contrast to inelastic scattering where kinetic 
energy of the photon is not-conserved. Photoelectric absorption refers to the attenuation or 
absorption of X-rays as the pass through an object. Phase contrast CT (PC-CT) has been 
developed for improved tomographic reconstructions from samples with low atomic Z, (e.g.), 
soft tissue. PC-CT uses the phase shift as the imaging signal, unlike conventional CT, relying 
only on absorption of X-rays (11). When X-rays penetrate matter, the index of refraction n of the 
material causes the electromagnetic wave to be absorbed and phase shifted, compared to an 
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electromagnetic wave propagating in free space as seen in Figure 3.9. The index of refraction n 
of a material is shown in the following equation (90): 
 
𝑛 = 1 − 𝛿 + 𝑖β 
 
The refractive index is a complex number, with δ describing the real phase shift of the 
wave, and iβ describing the imaginary change in amplitude as the wave is attenuated. δ and β are 
described in the following equations, respectively (90): 
 
𝛿 = (𝜆/2/𝜋)𝜌𝐴𝜎𝑝  
 
𝛽 = (𝜆/4/𝜋)𝜌𝐴𝜎𝑎  
 
Where λ is the wavelength of the light, ρa is the atomic density of the sample, σp is the 
phase cross-section, and σa is the absorption cross-section. As stated previously, σp is three orders 
of magnitude greater than σa for low Z materials. The real part of the refractive index δ describes 
the change in the wave inside the material with n refractive index, in respect to a wave 
propagating outside the material in free space. The phase shift of the wave results in a change in 
the propagation direction as well. The phase shift, direction change, and amplitude attenuation of 
a wave propagating through a material is shown below in Figure 3.9.  
 
 
 
[3.7] 
[3.8] 
[3.9] 
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Figure 3.9: The phase shift and attenuation of a wave travelling through a material of n 
refractive index are shown. Top: The shift in phase (ΔΦ) is shown in orange and the change in 
propagation direction (α) is shown in red. Bottom: the attenuation of the amplitude (Δ|E|) 
between I to I0, shown in green. Based from (2).  
 
There are several PCI methods currently in use, including analyzer based imaging, 
propagation based imaging (PBI), crystal interferometry, and grating based imaging. Each of 
these methods can also be applied to CT, with their own strengths and weaknesses. PBI phase 
contrast computed tomography (PC-CT) was used to collect the data for this thesis (90).  
Propagation based imaging PC-CT consists of a spatially coherent X-ray source, a sample 
some distance away, and a detector some distance away from the sample. Therefore, a small size 
X-ray source or a source far from the subject is needed to achieve the special coherency required 
for PBI. Synchrotron X-rays have been used numerous times for PBI imaging (9), (14), (82), 
(11), (91). The name of PBI derives from the experimental setup, as the detector is placed not 
immediately behind the sample like in conventional CT, but at some distance, allowing the 
refracted X-ray beam to propagate in free space before being detected as shown in Figure 3.10. 
The simple setup and minimal stability requirements are an advantage over other phase imaging 
modalities that require additional precise optical equipment.  
 
𝑛 = 1 − 𝛿 + 𝑖β 
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Figure 3.10: The scanning setup for PBI PC-CT imaging, showing Fresnel fringes forming as 
the wavefront propagates towards the detector. The further the detector position, the more the 
fringes form (92). 
 
Fresnel fringes are created by the coherent X-ray beam as it propagates away from the 
sample towards the detector. The interference fringes created are proportional to the second 
derivative of the phase wavefront. The fringes are seen as edge enhancement, where the 
interfaces between two materials of different density are more clearly observed (93). This could 
improve contrast between objects of different density within the same sample being imaged. 
PBI PC-CT was selected as the imaging modality for use in this research due to its 
relatively easy setup, relaxed constraints on stability, and improved soft tissue contrast for 
prostate visualization. All data collected on the BMIT-ID were collected using PBI PC-CT, 
which is often just referred to as PC-CT for simplicity.  
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Chapter 4: Materials and Methodology 
This chapter outlines the design process of the canine positioning device, and the design 
specifications of the device. There were two re-designs of the canine positioning device, 
described chronologically in the following sections. Three experiments were conducted on the 
material used to create the canine positioning device, each with the specific goal of generating 
the best possible PC-CT reconstruction of in situ canine prostates. These include the pre-design 
experiment on the dog holder (the Pawsitioner), a mathematical predication of beam attenuation 
on the first design, and a comparison between two potential support structures for the final 
design. A summary of the X-ray detectors used to collect data on the BMIT-ID beamline 
concludes this chapter. 
 
4.1 Positioning Device Design Overview 
This section covers the discussion of the positioning device and the specifications needed 
for the BMIT-ID beamline, and concludes with a discussion of the pros and cons of the different 
detectors available at the CLS for imaging on the BMIT-ID beamline.  
The specific objective of this research was to design, develop, and implement a canine 
positioning system for the BMIT-ID beamline, capable of imaging in situ dog prostates in both 
cadaver and live dogs. The canine positioning device was designed to restrain dogs in a vertical 
dorsal recumbency position to minimize the amount of tissue the beam would have to traverse to 
effectively image the prostate. The pre-design thought was to have the dog in this near vertical 
dorsal recumbent position, allowing for the scan’s axis of rotation to be centered on the canine 
prostate area, while reducing the amount of tissue attenuation length the beam would need to 
pass through. There are three potential axes of rotation allowed in 3D space, and the dog is 
required to spin on one of these axes during a PC-CT scan. The transverse plane of the dog in the 
abdominal and pelvic regions has the smallest tissue cross section area compared to the dorsal 
plane or the median plane, as seen in Figure 4.1. The transverse plane of the dog is represented 
with the dimensions X and Y. The median and dorsal planes through the abdominal and pelvic 
areas present a larger cross section though the dog, thereby maximizing the attenuation length of 
the x-ray beam through this tissue. Therefore, the dog should be held within the device in such a 
way as to allow a transverse section of the abdomen and pelvis through the imaging beam to 
minimize beam attenuation. The scan axis of the dog needed to align with the rotational axis of 
the imaging stage in the BMIT-ID hutch, on which the device would be fitted and rotated, as 
seen previously in Figure 3.8. Therefore, the final position of the dog during scanning was 
decided on, as the cranial-caudal anatomical line needed to align with the rotational axis of the 
stage, parallel to the walls of the imaging hutch. Through this chapter, the development of the 
canine positioning system is described. 
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Figure 4.1: The anatomical planes of the canine species, with the transverse (X and Y), 
median and dorsal planes shown, squared in red. The rotational axis of the dog within the canine 
positioning device is represented with the black arrow traversing from caudal to cranial. The 
location that the transverse plane traverses the dog is described as height, and is represented by 
Z. The transverse plane of the abdomen and pelvis has the smallest cross section, compared to 
both the median and dorsal planes (94). Reprinted with permission. 
 
4.1.1 Design Specifications 
The design of the device began with preliminary meetings between researchers from the 
University of Saskatchewan Prostate Cancer Research Team (USPT), including myself, 
Beamline Scientists from the CLS BMIT beamline and engineers from RMD Engineering Inc., 
who constructed the device. The device was specified to do the following: 
1) Provide structural stability to the dog while it was rotated during a PC-CT scan. 
2) Have minimal material and canine tissue in the path of the beam to reduce attenuation. 
3) Have material that was in the path of the beam be of a low atomic number with a low mass  
attenuation (μ/ρ) value. 
Y 
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4) Not exceed the maximum weight capability of the Canadian Light Source micro-beam 
radiation therapy (MRT) lift (130 kg: includes weight of device plus dog). 
5) Be compatible with and be able to support housing of the anesthetic equipment needed for  
live dog imaging.  
 
4.1.2 Pawsitioner 
The Pawsitioner is a commercially available product from AVAIL Concepts, IIC, Sedona, AZ 
(95). The Pawsitioner was designed for positioning anesthetized dogs for a number of 
applications, including ultrasonography, CT, MRI, dentistry, surgery, and myelography. The 
Pawsitioner is made of polyethylene, making it radio-transparent. The Pawsitioner is available in 
three sizes (24, 37 and 58 inches long) and is designed primarily to hold dogs of various sizes 
(small <15 kg, medium 15-30 kg and large dogs > 30 kg) during CT scans. A front and side view 
of a Pawsitioner can be seen in Figure 4.2.  
 
Figure 4.2: Front and side view of the Pawsitioner (95).  
 
A preliminary experiment was conducted on the BMIT-BM beamline to determine if the 
Pawsitioner would negatively affect reconstruction quality by being in the field of view during 
PC-CT scanning. It was hypothesized that the low mass attenuation and small cross section area 
of the Pawsitioner would not affect PC-CT reconstruction quality. If the Pawsitioner created 
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reconstruction artifacts compared to previous tests conducted on the BMIT-BM beamline with 
excised prostates, then another canine holder would need to be found or designed before moving 
forward with designs for a complete positioning device. If the image reconstruction quality was 
not affected, the designing of the positioning device could proceed using the Pawsitioner as the 
primary canine holding device. 
 
A sample of an excised formalin-fixed canine prostate was set in a polyethylene container, 
with a diameter of 4.5cm, and filled with clear gelatin (Knox, Oak Brook, IL). The gelatin was 
allowed to solidify overnight in a fridge. The container with the prostate/gelatin was then 
wrapped with store-bought beef steak to simulate the surrounding soft tissue around the prostate 
in a live dog for imaging purposes. The steak and container diameter was 8 cm. The 
steak/gelatin/prostate sample was then placed in the BMIT-BM hutch on the CT stage. The 
Pawsitioner was attached to the imaging stage and partially surrounded the prostate sample. A 
picture of the setup can be seen in Figure 4.3. The experiment would be considered successful if 
the reconstruction quality of the scan of the excised prostate was not affected compared to 
previous results generated on the BMIT-BM beamline that did not include the Pawsitioner 
device.  
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Figure 4.3: The experimental setup for the Pawsitioner test. Left is the overall setup on the CT 
stage. The blue dashed arrow indicates a close up of the excised canine prostate, set in gelatin 
and surrounded by steak, right. 
 
The sample was PC-CT scanned at 40 keV, with a 225 ms exposure time for each tomographic 
projection, and 3751 tomographic projections captured over 180° CT rotation. The resolution at 
the detector was 14 microns/pixel, with a total capture area of 3894 pixels x 235 pixels. The 
source to sample distance on the BMIT-BM beamline is 20.15 m, and the sample to detector 
distance was 5.84 m. The reconstruction results are shown in Figure 4.4. The data collected was 
reconstructed using NRecon, a software program designed by Bruker microCT (96).
  
 
 
Figure 4.4: A). A slice reconstruction of the PC-CT scan experiment test done with the Pawsitioner, excised canine prostate and steak. 
The reconstruction was performed in NRecon (96). A red box surrounds the thin slice of prostate tissue, and a blue arrow indicates 
steak. The polyethylene container is indicated with a dashed white arrow, and the Knox gelatin is indicated with a yellow arrow. The 
area within the red box is shown larger in Figure 4.5. B). A sample PC-CT reconstruction from an ex vivo canine prostate imaged on 
the BMIT – BM beamline. The white dashed arrows indicate the container, and the red arrow indicates the prostate. 
3
3
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Figure 4.5: A zoomed slice reconstruction of the PC-CT scan experiment test done with the 
Pawsitioner, excised canine prostate and steak. The prostatic tissue can be seen here, surrounded 
by Knox gelatin. Distinct tissue arrangements are apparent. This is the area within the red box 
seen in Figure 4.4. 
 
Previous experiments done on the BMIT-BM beamline with excised prostates set in gelatin 
produced similar results as to the test done with the Pawsitioner in the field of view, as seen in 
Figure 4.4. The reconstruction quality was not affected when compared to images from similar 
previous experiments conducted on the BMIT-BM beamline, supporting the original hypothesis 
that the low mass attenuation and small cross section area of the Pawsitioner would not affect 
PC-CT reconstruction quality. The Pawsitioner was therefore determined to be acceptable for 
restraining/supporting the dog in combination with the positioning device while imaging on the 
BMIT-ID beamline. Further requirements for the canine positioning device to be designed 
included:  
1) Provide structural stability to the dog while it was rotated during a PC-CT scan. 
2) Have minimal material and canine tissue in the path of the beam to reduce attenuation. 
3) Have material that was in the path of the beam be of a low atomic number with a low mass  
attenuation (μ/ρ) value. 
4) Not exceed the maximum weight capability of the micro-beam radiation therapy (MRT) lift 
(130 kg: includes weight of device plus dog). 
5) Be compatible with and be able to support housing of the anesthetic equipment needed for  
live dog imaging.  
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4.2 Preliminary Positioning Device Design 
An initial design was drafted, as shown in Figure 4.6. The design had a three-tiered base 
for gross adjustment of translational movement in the x-y direction with the base attaching to the 
top of the BMIT ID Beamline MRT lift. The base of the support structure has specially designed 
spaces for anesthetic equipment, including the oxygen tank, anesthetic gas vaporizer and 
scavenger, and isoflurane holder. The top of the Pawsitioner needs to be able to be attached to 
the support beam; this was accomplished using four screws. The base of the Pawsitioner was not 
attached to the base of the support in the initial design. With this design X-rays would enter 
parallel to the floor, and pass through the Pawsitioner and polycarbonate support and support as 
shown in the Figure 4.6. The polycarbonate support is shown in more detail in Figure 4.7 and 
Figure 4.8. 
 
Figure 4.6: A side view of the preliminary design of the canine positioning device, with the 
Pawsitioner indicated with a red arrow. The green arrow indicates the polycarbonate support 
structure. The anesthetic equipment attachments are indicated with black dashed arrows. The X-
ray beam path is indicated with black arrows. 
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Figure 4.7: (a) A side view of the polycarbonate preliminary canine positioning system support 
structure shaded in grey and (b) A 3D view. The Pawsitioner is not seen in above figures.  
 
 
Figure 4.8: The back, sides, and top blueprint for the polycarbonate preliminary support 
structure are shown. Initial units are in mm, inches shown in brackets.  
 
(a) (b) 
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 It was hypothesized that the reconstruction quality of the canine prostates held in the 
device may be negatively affected by the large beam attenuation length of the support structure. 
To test this hypothesis, this preliminary polycarbonate support structure was analyzed for beam 
attenuation, with results of the calculations shown in Table 4.1. As outlined in section 3.1.1, the 
attenuation (I/I0) of an object can be calculated using the mass attenuation coefficient (µ/ρ) and 
the density (ρ) of the sample, along with the attenuation length (x) of the beam.  
 
𝐼
𝐼0
= 𝑒−(
𝜇
𝜌⁄ ) 𝜌 𝑥 
 
Three paths through the polycarbonate supports were analyzed for beam attenuation, the 
minimum path travelled, the maximum path travelled, and realistic path travelled by the beam. 
The realistic path indicated where the prostate was likely to be located in the cadaver. The three 
beam paths are shown in Figure 4.9, (A) indicates the shortest, (B) the expected, and (C) the 
maximum attenuation length of the polycarbonate support. Three beam energies of 50 keV, 60 
keV, and 80 keV were selected for the attenuation analysis for each beam path. The energies 
selected were based on the specifications for the energy spectrum produced by the BMIT-ID 
wiggler, and the lower absorption of X-rays at higher photon energy. The three beam paths are 
parallel to the floor and perpendicular to the back plate. Polycarbonate has a μ/ρ of 0.024/cm, 
0.2244/cm, and 0.2052/cm at 50 keV, 60 keV, and 80 keV, respectively (97), and a density of 1.2 
g/cm2. 
 
Beam path 
through 
support 
Beam length 
though support 
(cm) 
Attenuation at 50 
keV (I/Io) 
Attenuation at 60 
keV (I/Io) 
Attenuation at 80 
keV (I/Io) 
A 2.54 0.471 0.566 0.594 
B 17.5 5.83 x 10-3 1.97 x 10-2 2.76 x 10-2 
C 27.5 3.08 x 10-4 2.09 x 10-3 3.54 x 10-3 
 
Table 4.1: Attenuation data for the beam paths of different lengths shown in Figure 4.9. 
Attenuation is calculated for 50, 60, and 80 keV beam energies. The smaller attenuation values 
indicate the greater attenuation of the beam. 
 
[3.1] 
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Figure 4.9: Three potential beam paths are shown bisecting the polycarbonate support. The 
beam attenuation lengths of A, B, and C are 2.54 cm, 17.5 cm, and 27.5 cm, respectively.  
 
It was determined that the polycarbonate support structure should not attenuate the beam 
by more than 10% of its original value, or reconstruction quality would decrease significantly 
(98). Therefore, the I/Io value must be greater than 0.90 for the beam path to produce reasonable 
reconstructions, i.e anything less than 0.90 I/I0 is undesirable. The smallest beam path through 
the polycarbonate support (Path A, 2.54 cm) reduced the beam intensity by 40.6% at the highest 
beam energy. The beam length traversing the support (Path B, 17.5 cm) at the expected prostate 
height attenuated the beam by 97.3% at 80 keV. At a length of 27.5 cm, the longest potential 
beam path through the polycarbonate support, the beam was attenuated by 99.6%.  The 
preliminary polycarbonate support design was therefore predicted to cause severe X-ray beam 
attenuation at certain angles in the beam, proving the hypothesis even at a minimum distance and 
high photon energy, and rejected. 
It was decided that the polycarbonate support structure should be redesigned to eliminate 
the material from the path of the beam while still providing stability for the dog to be imaged.  
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4.3 Secondary Positioning Device Design 
A second design of the canine positioning device was completed in February 2015.  The 
design is shown in Figure 4.10, with the vertical support structure from the previous design 
completely removed. The Pawsitioner is now attached to the support at its base. The three-tiered 
base remained unchanged. 
 
Figure 4.10: A side view of the secondary design of the canine positioning device, with the 
Pawsitioner indicated with a red arrow.  
 
 
Upon further discussion, the design in Figure 4.10 was rejected as the lack of support 
structure at the top of the Pawsitioner could allow for lateral movement and vibration during the 
imaging, which would be detrimental to the reconstruction quality (98). With only one 
attachment point at the base, it was a concern that the device would not allow for the stability 
needed to successfully perform PC-CT with a dog  
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4.4 Positioning Device Support Testing 
A compromise between structural stability and minimal attenuation length was needed 
for the canine positioning device. A second test was conducted on the BMIT-BM beamline to 
determine the optimal shape for a support structure to immobilize the top end of the Pawsitioner. 
Two potential shapes for the support structure were selected: a hollow polycarbonate tube with 
outer diameter 10 cm and a wall thickness of 0.7 cm; and a solid polycarbonate cylinder of 3.81 
cm diameter, as seen in Figure 4.11. The hypothesis for this testing was that since the hollow 
tube had the smallest beam attenuation length it would have fewer negative effects on PC-CT 
image reconstruction than the solid polycarbonate cylinder. The two shapes were chosen based 
on the uniformity of a circular support structure, and a high support to attenuation ratio, i.e. the 
tube and the cylinder can support a large amount of weight with a small attenuation length of the 
beam.  
 
 
Figure 4.11: Left: The polycarbonate tube with an outer diameter of 10cm and a wall thickness 
of 0.7cm, the center is hollow. Right: The polycarbonate cylinder with a thickness of 3.81cm. 
  
Polycarbonate was chosen as the material due to its relatively low mass attenuation 
coefficient and availability. A sample of formalin-fixed excised canine prostate was prepared and 
set in gelatin. The gelatin/prostate sample was again wrapped with store bought beef steak to 
better simulate canine tissue as described previously, with an overall 7 cm total diameter 
resulting. For concision the prostate/gelatin/steak sample is referred to as just the “pseudo-
prostate” sample though the rest of this section. The pseudo-prostate sample was placed within 
the small Pawsitioner and then attached to the CT stage in the BMIT-BM hutch. For two of the 
scans a canine pelvic bone was attached to the periphery of the pseudo-prostate sample. The 
canine pelvic bone was supplied from the Western College of Veterinary Medicine Anatomy 
department. A preliminary scan was done for a baseline reconstruction without the pelvic bone 
or either of the polycarbonate support structures. The initial scan was done at 35keV; with a 
capture time of 255 ms. Five scans were taken in total; the experimental setup summary of each 
scan is shown in Table 4.2. A total of 3751 projections were taken during a 180° rotation for all 
scans. The general setup for the tests are shown in Figure 4.12.  
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Figure 4.12: A top (birds eye) view of the experimental setup for the polycarbonate support test 
conducted on the BMIT-BM beamline. A) The blue solid circle indicates the solid polycarbonate 
tube. The red, black and orange areas represent the Pawsitioner, the steak, and the pseudo-
prostate, respectively. The blue arrow indicates the direction of rotation during a single scan. The 
pelvic bone is the white shape with the orange outline, and was only used in the final two scans. 
B) The blue hollow circle indicates the hollow polycarbonate cylinder; all other objects remain 
the same as in A.  
 
Scans Experimental Setup 
Capture 
Time (ms) 
Attenuation Length of 
Polycarbonate Support (cm) 
Scan 1 Prostate Sample 255 n/a 
Scan 2 
Prostate Sample + Polycarbonate 
Cylinder 
350 3.81 
Scan 3 
Prostate Sample + Polycarbonate 
Tube 
400 1.40 
Scan 4 Prostate Sample + Pelvic Bone 425 n/a 
Scan 5 
Prostate Sample + Polycarbonate 
Cylinder + Pelvic Bone 
250 3.81 
 
Table 4.2: A summary of the experimental setup for each scan performed on the BMIT-BM 
beamline. The capture time was adjusted during each scan to overcome the exponential drop in 
storage ring current at the CLS. Scans 1 and 4 did not have the polycarbonate support structure 
during the scans and therefore do not have an attenuation length of polycarbonate support. 
 
 
Scans 1, 2, and 3 were used to determine the optimal shape for the polycarbonate support 
structure design. Scans 4 and 5 were auxiliary tests to determine if the pelvic bone would be 
detrimental to the ability to reconstruct the CT data. The polycarbonate supports in each of the 
scans was placed 18.5cm radially from the center of rotation on the CT stage. A radial distance 
of 18.5 cm was chosen as this was likely to be the actual distance of the support from the prostate 
in the final draft of the design. Data from all five scans were reconstructed using NRecon. A total 
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of 173 slice reconstructions were generated from each scan, with a pixel size of 13.9 microns, 
and a resolution of 3987x3981 pixels. 
 A board certified veterinary radiologist compared the scan reconstruction qualities 
against one another. This was done to determine the best candidate for the support structure 
design. The veterinary radiologist was blinded to the experimental setup for each reconstructed 
image - three sample reconstructions from each scan were evaluated. A random number 
generator was used to select the slice height of the images to be evaluated - slices 87, 155, and 68 
were called Tests 1, 2, and 3, respectively. The five scan slices of each height were given a score 
from 1-5, with 1 being the highest quality reconstruction and 5 being the poorest reconstruction 
quality with the most artifact present. Each scan reconstruction was performed with the same 
parameters selected for scan 1 in NRecon, to reduce any biases in the reconstruction process. The 
results of the three reconstruction quality assessments done by the veterinary radiologist are 
shown in Table 4.3. Figure 4.13 shows reconstructions from scan 3 and scan 1 from test 2; (a) 
and (b), respectively. 
 
Reconstruction Quality 
(1 = High, 5 = Poor) 
Test 1 
(Slice Height 87) 
Test 2 
(Slice Height 155) 
Test 3 
(Slice Height 68) 
1 Scan 3 Scan 3 Scan 3 
2 Scan 2 Scan 1 Scan 2 
3 Scan 4 Scan 4 Scan 1 
4 Scan 5 Scan 2 Scan 5 
5 Scan 1 Scan 5 Scan 4 
 
Table 4.3: A summary of the results from the reconstruction quality assessment performed by 
the veterinary radiologist. The row denoted with 1 represents the reconstructions with the highest 
quality, 5 with the poorest reconstruction quality.  
 
It was determined that scan 3 had the best reconstruction quality of all three quality 
assessment tests. As shown in Table 4.3, scan 3 contained the prostate sample and polycarbonate 
hollow tube and was determined to have the highest reconstruction quality in all three tests. 
Therefore, from these results, it was decided that there should be a support for the upper end of 
the Pawsitioner constructed out of hollow polycarbonate tubing, in agreement with the 
hypothesis that since the hollow tube had the smallest beam attenuation length it would have 
fewer negative effects on PC-CT image reconstruction than the solid polycarbonate cylinder
    
 
 
 
 
 
 
Figure 4.13: Examples of reconstructions assessed by the veterinary radiologist. These two slices are from the slice height of 155, test 2. (a) shows 
the reconstruction from scan 3, (b) shows the reconstruction from scan 1. Prostate tissue is indicated with white arrows in both (a) and (b).
4
3
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4.5 Final Canine Positioning Device Design 
The final product after manufacturing and assembly can be seen in Figure 4.14 (a). The final 
design is shown in Figure 4.14 (b).  The final design met the requirements described in section 
4.1.1:  
1) Provide the required structural stability to the dog while it was rotated during a PC-CT  
scan. 
2) Have minimal material and canine tissue in the path of the beam to reduce attenuation. 
3) Have material that was in the path of the beam be of a low atomic number with a low mass  
attenuation (μ/ρ) value.  
4) Not exceed the maximum weight capability of the micro-beam radiation therapy (MRT) lift  
(130 kg: includes weight of device plus dog). 
5) Be compatible with and support anesthetic equipment needed for live dog imaging.  
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Figure 4.14: (a) A side view of the final design of the canine positioning device, with the 
Pawsitioner indicated with a red arrow. The polycarbonate support tube is indicated with a 
dashed black arrow. (b) A side view of the final draft design approved by the USPT, with the 
arrows indicating the same structures as in (a). 
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4.6 X-ray Detectors 
The concluding section of Chapter 4 covers the X-ray imaging detectors used on the BMIT-
ID beamline at the CLS. For this thesis three X-ray imaging detectors were used to collect data. 
The majority of the canine cadavers were imaged with a Photonic Science Fiber Optic Camera 
(XDI-VHR 90) (99). With funding from the Saskatchewan Health Research Foundation Phase 
Two grant, the USPR was able to purchase another X-ray detector, the Photonic Science Fiber 
Optic Camera (X-ray SCMOS) (100). A third detector, a Hamamatsu Flat Panel Sensor Detector 
(C9252DK-14) was used to collect data on the final canine cadaver images, as well as several of 
the live dogs imaged (100). The specifications of each of the detectors are shown below in Table 
4.4.  
Table 4.4: Specifications for each of the three X-ray detectors used to collect data on the BMIT-
ID beamline (100). 
 
The important distinction between the cameras is their frame rate, where FPS stands for 
frames-per-second. The higher the frame rate, the more images can be captured in a shorter 
amount of time, which reduces the scan time. A short scan time is desirable due to motion 
artifact, which is discussed under 5.2. Any movement of the object being scanned negatively 
affects the quality of the reconstruction, creating motion artifacts as seen in Figure 4.15, and 
therefore quicker scan times allow for less movement to occur. 
Detector 
Field of View 
(mm) 
Effective 
Pixel Size 
(microns) 
Energy 
Range 
(keV) 
Frame 
Rate 
(FPS) 
Photonic Science Fiber Optic Camera 
(XDI-VHR 90) 
74 x 49 18.7 5 - 100 0.5-2 
Photonic Science Fiber Optic Camera 
(X-ray SCMOS) 
105 x 52 25.3 5 - 100 18-25 
Hamamatsu Flat Panel Sensor Detector 
(C9252DK-14) 
243 x 10 100 20 - 90 146 
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Figure 4.15: (a): Motion artifact of a transverse CT reconstruction of a human abdomen. (b) A 
transverse CT reconstruction of a human abdomen without motion artifact (101).   
 
 
A typical PC-CT scan takes approximately 4000 tomographic projections over 180°. The 
number of projections captured by the detector during a PC-CT scan should be approximately the 
same as the number of columns in the detectors field of view. The total scan time for one view 
can be determined by dividing the total number of projections to be taken over the frame rate of 
the detector. Therefore, the Hamamatsu detector can capture one view of 4000 tomographic 
projections in approximately 27 seconds, making it the fastest detector available at the CLS 
BMIT compared to the XDI-VHR 90 and the X-ray SCMOS, which would take 2000 seconds 
(33.33 minutes) and 160 seconds (2.66 minutes) each to capture 4000 tomographic projections, 
respectively. The longer the scan time, the more the potential for the object being imaged to 
move, consequently the Hamamatsu Flat Panel would be the most desirable of the available 
detectors to prevent motion artifacts. However, the pixel size of the Hamamatsu detector is the 
largest of all three, giving it the poorest resolution. The pixel size of the detector directly effects 
the resolution in the reconstructions. As a general rule for CT, no object smaller than the pixel 
size can be discerned in the reconstructions (93). With this rule, the smallest object detectable by 
the Hamamatsu Flat Panel detector is 100 microns, while the XDI-VHR 90 and X-ray SCMOS 
can detect object of 19 and 25 microns, respectively. Therefore, the Hamamatsu Flat Panel may 
have the highest tolerance to movement, but is less desirable due to the large pixel size. For 
comparison, high resolution conventional CT has a maximum pixel resolution of 200 microns, 
and nuclear magnetic resonance imaging has a resolution of around 1000 microns (102), (103). 
  The differences of the field of view (FOV) is also important between the detectors. The 
Hamamatsu Flat Panel detector has the smallest FOV, with an area of 2430 mm2, the XDI-VHR 
90 Photonic Science detector has an intermediate FOV of 3626 mm2, and the X-ray SCMOS 
Photonic Science has the largest FOV at 5460 mm2. The width of the detector corresponds to the 
area of the reconstruction due to the algorithms used to reconstruct the CT data. The height of the 
detector corresponds to how many reconstructions can be generated from a data set. For 
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example, the Photonic Science Fiber Optic Camera (XDI-VHR 90) at full field would generate 
approximately 2575 reconstructions. Remember that reconstructions can also be referred to as 
slices. The number of reconstructions generated can be estimated by dividing the height of the 
detector in microns by the pixel size, also in microns. In reality, the XDI-VHR 90 will not 
produce that many reconstructions because of the limited height of the synchrotron X-ray beam. 
As discussed previously in section 3.2, the size of the beam at the sample location in the BMIT-
ID imaging hutch is approximately 11mm high x 220mm wide. Therefore, to get a realistic 
estimate of the number of reconstructions generated by each of the detectors, the beam height 
needs to be divided by the pixel size instead. This method gives a more accurate representation 
of the reconstructions generated for each view. The smaller the pixel size, the more 
reconstructions are generated. The XDI-VHR 90, X-ray SCMOS, and Hamamatsu Flat Panel 
generate 580, 440, and 110 reconstructions, respectively. The use of the detectors is discussed 
further in section 5.2.   
The Hamamatsu Flat Panel’s pixel size make it ineffective for PC-CT imaging. The 100-
micron pixel size is too large to detect the phase change signal from the interfaces between 
tissues in the dog. Both of the Photonic Science detector’s pixels’ sizes are sufficient to detect 
the edge enhancement effect generated from PC-CT imaging (14), (9).  
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Chapter 5: Implementation of Canine Positioning Device 
 
5.1 Overview 
The specific objective of this thesis was to design, develop and implement a canine 
positioning system for the BMIT-ID beamline that would allow safe and effective imaging of 
live dogs. This section covers the implementation of the device. This chapter covers two main 
issues discovered and addressed during the implementation of the device: Positioning / Motion 
Artifact, and Locating the Prostate. Preventing motion artifact of the dog within the canine 
positioning device was a challenging issue. Several attempts at different methods of 
immobilization were tested to try to secure the dog for imaging. Section 5.2 goes over the 
different immobilization methods tested during the cadaver imaging. Locating the prostate for 
imaging was the second issue that was identified and addressed during the course of this 
research, which is discussed in section 5.3. 
The canine positioning device was designed to allow for imaging of an in-situ canine prostate 
on the BMIT-ID beamline at the CLS. To this effect, a total of 15 dog cadavers and six live dogs 
were imaged using the canine positioning device between June 2015 and May 2016. The cadaver 
dogs were sourced for the Saskatoon Society for the Prevention of Cruelty to Animals, and were 
all a variety of breeds and sizes. The cadaver dogs were frozen post-mortem and kept in a freezer 
until two days before the experimental beam time at the CLS, when they were allowed to thaw at 
room temperature. The freezing and thawing of the cadavers altered the tissue structure, but this 
was unavoidable as no recently deceased cadavers could be sourced for the experiments. The live 
dog imaging occurred last, with all six dogs being imaged in May 2016. Each cadaver dog and 
live dog was imaged using PC-CT, the imaging modality previously discussed in section 3.3. 
The live dogs used for this research were scheduled for euthanizing for reasons not related to this 
thesis. For each of the cadaver and live dogs imaged a similar protocol was followed, where the 
dogs were immobilized in the canine positioning device, put up onto the stage in the BMIT-ID 
hutch and imaged using PC-CT.  Due to the exploratory nature of this research, the imaging 
protocol used for each dog was modified and adjusted, based on lessons learned from imaging of 
previous dogs, and always with the specific goal of improving the PC-CT image reconstruction 
quality. Therefore, the imaging protocol for the first cadaver dog imaged is dramatically different 
from the last. The protocols for imaging live dogs were built off of the cadaver imaging protocol, 
but with several adjustments required to account for anesthesia and monitoring required. Table 
5.1 describes the imaging parameters for the cadaver dogs 1-15, and Table 5.2 describes the 
parameters used for live dog imaging. 
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Table 5.1 – Overview of Cadaver Dog PC-CT 
Dog 
Cadaver 
Date Imaged 
(DD/MM/YY) 
Filters 
in 
Beam 
View 
Height 
(mm) 
Magnetic 
Field 
Strength 
(T) 
Views 
Energy 
of 
Scan 
(keV) 
Capture 
Time 
(ms) 
Number of 
Projections 
Detector  
1 11/06/15 
1 mm 
Al, 
0.5 
mm 
Cu 
8.4 2.5 
1-1 45 40 3600 
XDI-
VHR 90 
1-2 45 25 3600 
1-3 45 32 3600 
1-4 45 25 3600 
2 12/06/15 
1 mm 
Al, 
0.5 
mm 
Cu 
7.0 2.5 
2-1 45 27 1800 
XDI-
VHR 90 
2-2 45 25 1000 
2-3 45 30 1800 
2-4 60 70 1000 
2-5 70 22 3600 
3 24/06/15 
1 mm 
Al, 
0.5 
mm 
Cu 
7.3 2.5 
3-1 50 170 3600 
XDI-
VHR 90 
3-2 70 200 3600 
3-3 80 200 3600 
3-4 60 250 3600 
3-5 70 170 3600 
3-6 90 60 3600 
4 25/06/15 
1 mm 
Al, 
0.5 
mm 
Cu 
7.5 2.5 
4-1 90 50 3600 
XDI-
VHR 90 4-2 90 450 3600 
5 30/07/15 
1 mm 
Al, 
0.5 
mm 
Cu 
7.7 2.5 
5-1 60 900 3600 
XDI-
VHR 90 
5-2 60 900 3600 
5-3 60 500 3600 
6 11/09/15 
1 mm 
Al, 
0.5 
mm 
Cu 
5.5 2.5 
6-1 60 180 3600 
XDI-
VHR 90 6-2 60 60 3600 
7 12/09/15 
1 mm 
Al, 
0.1 
mm 
Cu 
5.5 2.5 
7-1 80 140 3600 
XDI-
VHR 90 
7-2 80 140 3600 
7-3 80 700 3600 
8 12/12/15 
1 mm 
Al, 
180 
mm 
Lucite 
7.2 2.5 
8-1 70 250 3600 
XDI-
VHR 90 
8-2 70 300 3600 
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9 27/01/16 
1 mm 
Al, 
160 
mm 
Lucite 
8.7 2.5 
9-1 70 600 1200 
XDI-
VHR 90 
9-2 70 150 1200 
10* 22/04/16 
1 mm 
Al, 
220 
mm 
Lucite 
9.3 2.5 n/a n/a n/a n/a 
XDI-
VHR 90 
11 06/05/16 
1 mm 
Al, 
140 
mm 
Lucite 
8.7 3.0 
11-1 60 1500 1501 
XDI-
VHR 90 
11-2 60 1000 3751 
11-3 60 950 1250 
12 17/05/16 
1 mm 
Al, 
160 
mm 
Lucite 
8.7 3.0 
12-1 60 1500 3751 
XDI-
VHR 90 
12-2 60 100 4000 
X-ray 
SCMOS 
12-3 60 100 4000 
12-4 60 100 2000 
12-5 60 100 4000 
13 21/05/16 
1 mm 
Al, 
160 
mm 
Lucite 
8.2 3.0 
13-1 60 95 4000 
X-ray 
SCMOS 
13-2 60 95 4000 
13-3 60 95 4000 
13-4 60 95 4000 
13-5 60 95 4000 
13-6 60 95 4000 
13-7 60 45 8000 
13-8 60 95 4000 
14 21/05/16 
1 mm 
Al, 
160 
mm 
Lucite 
8.2 3.0 14-1 60 195 8000 
X-ray 
SCMOS 
15 22/05/16 
1 mm 
Al, 
160 
mm 
Lucite 
8.0 3.0 
15-1 60 95 4000 X-ray 
SCMOS 15-2 60 95 4000 
15-3 60 10 2000 
Flat 
Panel 
15-4 60 10 2000 
15-5 80 10 2000 
15-6 80 10 2000 
15-7 90 10 2000 
15-8 90 10 2000 
Table 5.1: An overview of the canine cadaver imaging done at the CLS between June 2015 and 
May 2016. * Dog 10 was not imaged using PC-CT, and was only used to monitor for motion, but 
is included in this list because the device was still used. The three different detectors used are the 
Photonic Science Fiber Optic Camera XDI-VHR 90 (XDI-VHR 90), Photonic Science Fiber 
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Optic Camera X-ray SCMOS (X-ray SCMOS) and the Hamamatsu Flat Panel Detector (Flat 
Panel). 
 
Table 5.2 – Overview of Live Dog PC-CT 
Live 
Dog 
Imaged 
Date Imaged 
(DD/MM/YY) 
Filters 
in 
Beam 
View 
Height 
(mm) 
Magnetic 
Field 
Strength 
(T) 
Energy 
of 
Scan 
(keV) 
Views 
Capture 
Time 
(ms) 
Number of 
Projections 
Detector 
1 29/05/16 
1 mm 
Al, 
160 
mm 
Lucite 
8 3 60 
1 
95 4000 
X-ray 
SCMOS 
2 
3 
4 
2 22/05/16 
1 mm 
Al, 
160 
mm 
Lucite 
8.2 3 60 
1 
95 4000 
X-ray 
SCMOS 
2 
3 
3 28/05/16 
1 mm 
Al, 
160 
mm 
Lucite 
8 3 90 
1 27.2 1900 
Flat 
Panel 
2 27.2 1900 
3 27.2 1900 
4 27.2 1900 
5 27.2 760 
6 61.2 1900 
7 61.2 1900 
8 61.2 760 
4 28/05/16 
1 mm 
Al, 
160 
mm 
Lucite 
8 3 90 
1 27.2 1900 
Flat Panel 
2 27.2 1900 
3 27.2 1900 
4 27.2 1900 
5 27.2 760 
6 61.2 1900 
7 61.2 1900 
8 61.2 760 
9 61.2 1900 
10 61.2 1900 
11 61.2 1900 
5 29/05/16 
1 mm 
Al, 
160 
mm 
Lucite 
8 3 60 
1 95 4000 
X-ray 
SCMOS 
2 195 2000 
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6 25/05/2016 
1 mm 
Al, 
160 
mm 
Lucite 
8 3 60 
1 
10 2000 Flat Panel 
2 
3 
4 
5 
6 
7 
8 
9 
 
Table 5.2: An overview of the live dogs imaged at the CLS BMIT-ID beamline using the canine 
positioning device during May 2016. The two different detectors used are the Photonic Science 
Fiber Optic Camera X-ray SCMOS (X-ray SCMOS) and the Hamamatsu Flat Panel Detector 
(Flat Panel). 
 
 
5.1.1 Positioning 
The Pawsitioner® comes with several hook-and-loop straps (i.e. “Velcro”) used to hold the 
dog stable during use. The device was originally designed to hold dogs in a supine horizontal 
position for conventional CT imaging (95). As described previously, the canine positioning 
device holds the dog in a near vertical position in order to minimize the amount of the subject the 
beam will have to traverse, and to minimize the radiation exposure of the dog. At the start of this 
project it was not known if the hoop-and-loop straps would be sufficient to support the dog 
during imaging. Therefore, for the first dog imaged, only the hook-and-loop straps were used to 
hold the dog within the positioning device during scanning, as shown in Figure 5.1. Using only 
these straps to secure the cadaver in the device did not prove to be sufficient for immobilizing 
the dog during scanning. The dog was visibly seen sliding down in the Pawsitioner during the 
duration of the scan, and therefore a different method of securing the dogs were investigated. 
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Figure 5.1: Cadaver 1imaged using the canine positioning device. The dog’s front and rear legs 
are secured with the hook-and-loop straps, indicated with the black arrows. The orange straps 
across the abdomen is vet wrap, used to secure the black padding (towels) seen bilaterally 
between the cadaver and the Pawsitioner. 
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For Cadavers 2-8 a Ruffwear® Load Up™ Harness (Bend, OR), a canine travel harness 
designed to restrain dogs during transport was used to help immobilize the dogs, and for 
cadavers 9-15 a Walkabout™ Front harness, (Santa Cruz, CA) a sling device to provide extra 
support and help a dog stand and walk with orthopedic or neurologic gait problems was utilized.  
The hook-and-loop straps were also used along with their respective harnesses to secure the 
cadaver for imaging.  The Load Up™ and Walkabout™ harnesses, used in their intended form, 
can be seen in Figure 5.2. Figures 5.3 and 5.4 show dog cadavers secured in the canine 
positioning device with the Load Up™ and Walkabout™ harnesses, respectively. 
 
 
Figure 5.2: (a): The Walkabout™ Front Harness (Santa Cruz). (b): The Ruffwear® Load Up™ 
harness (Bend, OR) (104), (105). 
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Figure 5.3: Cadaver two secured using the Ruffwear® Load Up™ harness (red arrow), and the 
hook-and-loop straps (white arrows) within the positioning device for imaging. 
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Figure 5.4: An example of a dog cadaver secured into the canine positioning device by the 
Walkabout™ front harness. The harness is indicated by a red arrow, and the hook-and-loop straps 
indicated black arrows.  
 
5.2 Motion Artifact 
Motion artifact refers to the movement of the dog within the canine positioning device caused 
by gravity. For the first several month of data collection it was not known that motion artifact 
was a major issue. This was due to a variety of other confounding issues, such as technical 
problems with BMIT and the CLS, positioning of the cadaver within the device, beam energy 
selection, tomographic projection capture number, technical problems with the X-ray detector, 
and difficulty in locating the prostate for imaging.  It was only by examination of previously 
collected data from the first eight cadavers and multiple consultation with researchers from the 
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CLS that motion was identified as a major obstacle. In retrospect, both the Load Up™ and 
Walkabout™ harnesses did not sufficiently immobilize the cadaver dogs for imaging. There was 
a large amount of motion artifact in the scans obtained using these devices in conjunction with 
the Pawsitioner, making reconstruction quality extremely poor.  The Walkabout™ harness was 
used for all of the live dog imaging as well, along with a modification to the device, described in 
section 5.1.3. The first time the motion artifact was calculated was after the imaging of the ninth 
dog cadaver, and each subsequent imaging shift was use to try to reduce the motion of the dog 
during scanning. This section describes how each of the cadavers were secured into the canine 
positioning device, and the steps taken to reduce motion.  
Due to the mathematical nature of the algorithms used to do the CT reconstructions, the object 
being scanned needs to remain near stationary while scanned (82). For small samples, such as 
excised canine prostates in a jar of gelatin, this is not an issue, but for larger samples, such as a 
cadaver, this issue proves very challenging. In clinical CT, where the patient is supine, the 
immobilization issue is minimal, and usually revolves around the involuntary movements of the 
body, such as breathing and heart movements (98). The scan time of clinical CT is also several 
orders of magnitude shorter than synchrotron PC-CT, around 10 seconds per scan, therefore 
greatly reducing the risk of motion artifacts during clinical CT scanning compared to PC-CT. 
Due to the near-vertical nature of which the cadaver for PC-CT imaging in the canine positioning 
device, extra care was taken to secure the cadaver to help limit slumping due to the force of 
gravity.  
The maximum amount of movement allowed during a scan is dependent on the imaging 
detector’s pixel size and scan time (82).  This is because the algorithms used for CT 
reconstruction assumes no movement of the object during the entire scan. Only a slight amount 
of movement can be tolerated for the reconstructions to be accurate (98). The tolerated 
movement size is equal to the pixel size of the detector. Therefore, the Hamamatsu Flat Panel has 
the highest tolerance to movement per scan, the X-ray SCMOS in intermediate, and the XDI-
VHR 90 has the least. The other important factor to consider when dealing with the motion issue 
is the total scan time required for each view. The shorter the scan time, the less time there is for 
the cadaver to slump. As described previously in section 4.6, the Hamamatsu Flat Panel detector 
has the shortest scan time, compared to the other two detectors, of approximately 27 seconds for 
a 180° scan of 4000 tomographic projections. With this information, a maximum movement 
tolerance for the detector can be estimated by dividing the pixel size by the scan time, giving a 
tolerance of 3.7 µm/s for the Hamamatsu Flat Panel detector.  
 
𝑀𝑜𝑡𝑖𝑜𝑛 𝑇𝑜𝑙𝑒𝑟𝑎𝑛𝑐𝑒 (µ𝑚/𝑠) =  
𝐷𝑒𝑡𝑒𝑐𝑡𝑜𝑟 𝑃𝑖𝑥𝑒𝑙 𝑆𝑖𝑧𝑒 (µ𝑚)
𝑆𝑐𝑎𝑛 𝑇𝑖𝑚𝑒 (𝑠)
 
 
The movement tolerance describes the maximum “speed” or distance in a given time the 
cadaver can be moving before the reconstruction quality is affected resulting in motion artifacts. 
To increase the motion tolerance, either the scan time can be reduced or the pixel size can be 
[5.1] 
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increased. However, the pixel size is a physical property of the detector, and therefore the only 
practical approach to increase the movement tolerance is to reduce the scan time. Two steps can 
be taken to decrease the scan time: decrease the amount of tomographic projections captured 
over 180°, and increasing the frame rate of the detector. For example, if the number of 
tomographic projections is halved, the motion tolerance will double.  
 
𝑆𝑐𝑎𝑛 𝑇𝑖𝑚𝑒 (𝑠) =
# 𝑜𝑓 𝑇𝑜𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑖𝑐 𝑃𝑟𝑜𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠 𝑇𝑎𝑘𝑒𝑛
𝐹𝑟𝑎𝑚𝑒 𝑅𝑎𝑡𝑒 (𝑠−1)
 
 
The motion tolerance of any detector is not perfect. That is to say, the formula assumes near 
uniform linear motion of the cadaver being imaged, which is highly unlikely. The motion 
tolerance of the Hamamatsu Flat Panel detector only holds true if the cadaver moves in one 
dimension at a constant speed of less than 3.7 µm/s. In reality, the cadaver being imaged can 
move in multiple dimensions, at multiple rates, and experiences variable accelerations for the 
duration of the scan. This means that parts within the cadaver may be moving at different rates in 
different directions while held in the positioning device during scanning which is contrary to the 
requirement of a near stationary sample being imaged. The motion tolerance equation does not 
describe the effect that motion during scanning will have on reconstruction quality, rather the 
equation is only a tool to help explain that even microscopic movements of the cadaver can 
effect reconstruction quality. The equation does not describe a movement threshold which after 
crossing will immediately result in poor reconstructions. 
One way to assess motion post-scanning is to take the first tomographic projection and 
compare it to the last horizontally inverted tomographic projection of the scan. This is called a 
motion artifact test. The first projection is taken at 0° and the last at 180°, and therefore they 
should be mirror images of each other. By horizontally inverting the final tomographic 
projection, a direct comparison can be made between the initial and final projection images. If 
the sample has been completely stationary during scanning, the inverted final projection should 
exactly overlay the initial projection. An example of a perfect scan (i.e. one without any cadaver 
motion) can be seen in Figure 5.5, though it is artificially made and only for example purposes. 
 
 
 
 
 
[5.2] 
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Figure 5.5: An example of a scan without any sample motion, the top image is the initial 
tomographic projection at 0° and the bottom image is the final at 180°. Notice that they are 
mirror images of one another. This figure was generated by taking the initial projection and 
making a copy imaged inverted horizontally. This image is from the fifth view of cadaver 2. 
Iodine contrast agent was injected into the bladder of the cadaver through a urethral catheter. The 
bladder can be seen in both the top and bottom image as the dark semi-circle, indicated with the 
white arrow in each. The prostate area is indicated with a white box. 
 
The real initial and final tomographic projection of the fifth view of the second dog are shown 
below in Figure 5.6. The movement of the bladder is extremely apparent when comparing the 
images together. The bladder moved 321 pixels horizontally and 258 pixels vertically, translating 
into a movement of 5.4 mm horizontally and 4.3 mm vertically. Interestingly, the bone in the 
same scan moves less vertically but more horizontally compared to the bladder. The bone 
appears to move 6.4mm horizontally and only 0.2mm vertically from the first to last projection.  
 
 
Figure 5.6: The initial (top) and final (bottom) tomographic projections of the fifth view from 
cadaver 2 scanned using the canine positioning device. The bottom image has been flipped 
horizontally. The movement of the bladder is extremely apparent when comparing the top and 
bottom image, shown with a white arrow. Bone movement is harder to see, but is still apparent, 
shown with black arrows.  
 
ImageJ, a software used for medical imaging, was used to measure the distances from Figure 
5.5 and 5.6. The view shown above in Figure 5.6 has a low movement tolerance of 4.72 x 10-3 
µm/s due to its large scan time of 60 minutes. The 60-minute scan time is due to the low frame 
rate of the detector used to capture this view, the Photonic Science Fiber Optic Camera XDI-
VHR 90. The apparent movement of the bladder was 6.9 mm over the entire scan, assuming a 
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linear relationship between the movement of 5.4 mm horizontal and 4.3 mm vertical. A 
movement of 6.9 mm translates to a bladder motion of 2.7 µm/s, several order of magnitudes 
greater than the movement tolerance of the scan. The bone in the same view has a slightly lower 
motion of 2.5 µm/s. Figure 5.7 shows a montage of the view shown above, with several 
tomographic projections between the beginning and end of the scan. This figure shows how the 
bladder slumps significantly more than the rest of the objects within the view.  
Due to the movement of the cadaver during scanning, the quality of the reconstructions was 
low, as seen in Figure 5.8. No soft tissue contrast is apparent, but a rough figure of bone can be 
seen on the left of the reconstructed image. The large white oval shape is the bladder filled with 
contrast agent, but the shape is undefined. Iodine based contrast agent is used to better locate the 
prostate, discussed further later. The speckles in the top right of the image is thought to be fecal 
matter, indicated with a yellow arrow. The prostate cannot be seen in Figure 5.8, nor in any of 
the reconstructions from this second cadaver.   
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Figure 5.7: A montage of the fifth view from cadaver 2. The top and bottom images represent 
the initial and final tomographic projections of the scan, respectively. The ten images between 
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show the vertical displacement of the bladder during the scan. The bladder is indicated with a 
white arrow in each of the twelve images. 
 
 
 
Figure 5.8: A reconstruction from the fifth view of cadaver 2 with the canine positioning device. 
The head of the femur, bladder, and fecal matter are indicated with a red, white, and yellow 
arrow, respectively. 
 
The highest quality reconstructions from the 15 cadavers imaged came from the third 
dog, a small, long-haired dachshund, perhaps because of the small size of the dog. The scans of 
this cadaver took approximately 60 minutes, and were captured with the Photonic Science Fiber 
Optic Camera XDI-VHR 90. The scans had a calculated movement tolerance of 4.7 x 10-3 µm/s. 
The higher quality of the reconstructed images is related to the movement speed of the third dog, 
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approximately 0.011 µm/s. The movement speed of this cadaver is two orders of magnitude 
smaller than for cadaver 2, and therefore much closer to the movement tolerance required for 
successful scanning, 4.7 x 10-3 µm/s. An example reconstruction from dog three can be seen in 
Figure 5.9. The pelvic bone, penile tissue, and urethral catheters are evident in 5.9 and the rough 
area of the prostate can be seen. The movement tolerance for dogs 1 – 15 are shown in Table 5.3. 
To address the motion issue, the canine positioning device was modified, as described below in 
5.1.3. Motion artifact tests were not conducted on the live dogs due to wanting to keep the 
radiation dose delivered as low as reasonably achievable, and these tests expose the dogs to a 
large amount of extra dose.  
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Figure 5.9: A reconstruction from the second view from cadaver 3 with the canine positioning 
device. The pelvic bone, penile tissue, and urethral catheters are indicated with a red, white, and 
yellow arrow, respectively. The same catheters can be seen twice due to the catheter passing 
through the penis and the prostate. The rough area of the prostate is marked with the black circle.   
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Table 5.3 – Movement Tolerance of PC-CT Scans Using Canine Cadavers 
Dog View 
# of 
Tomographic 
Projections 
Capture 
Rate 
(FPS) 
Pixel 
Size 
(µm) 
Scan 
Time 
(S) 
Movement 
Tolerance 
(µm/s) 
Apparent 
movement 
(µm/s) 
Detector 
 
1 
1 3600 1 17 3600 0.00472 1.99 
XDI-
VHR 90 
 
2 3600 1 17 3600 0.00472 1.98  
3 3600 1 17 3600 0.00472 1.85  
4 3600 1 17 3600 0.00472 1.88  
2 
1 1800 1 17 1800 0.00944 4.17 
XDI-
VHR 90 
 
2 1000 1 17 1000 0.017 6.63  
3 1800 1 17 1800 0.00944 3.86  
4 1000 1 17 1000 0.017 6.58  
5 3600 1 17 3600 0.00472 6.90  
3 
1 3600 1 17 3600 0.00472 0.27 
XDI-
VHR 90 
 
2 3600 1 17 3600 0.00472 0.15  
3 3600 1 17 3600 0.00472 0.0283  
4 3600 1 17 3600 0.00472 0.10  
5 3600 1 17 3600 0.00472 0.0633  
6 3600 1 17 3600 0.00472 0.12  
4 
1 3600 1 17 3600 0.00472 0.30 XDI-
VHR 90 
 
2 3600 1 17 3600 0.00472 0.18  
5 
1 3600 1 17 3600 0.00472 2.70 
XDI-
VHR 90 
 
2 3600 1 17 3600 0.00472 2.53  
3 3600 1 17 3600 0.00472 3.00  
6 
1 3600 1 17 3600 0.00472 0.47 XDI-
VHR 90 
 
2 3600 1 17 3600 0.00472 0.48  
7 
1 3600 1 17 3600 0.00472 0.35 
XDI-
VHR 90 
 
2 3600 1 17 3600 0.00472 0.42  
3 3600 1 17 3600 0.00472 0.44  
8 
1 3600 1 17 3600 0.00472 0.77 XDI-
VHR 90 
 
2 3600 1 17 3600 0.00472 0.87  
9 
1 1200 1 17 1200 0.0142 1.23 XDI-
VHR 90 
 
2 1200 1 17 1200 0.0142 1.13  
10 1 n/a n/a n/a n/a n/a 0.0189 
XDI-
VHR 90 
 
11 
1 1501 1 17 1501 0.0113 0.78 
XDI-
VHR 90 
 
2 3751 25 25 150.04 0.167 0.64  
3 1250 25 25 50 0.5 0.25  
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12 
1 3751 25 25 150.04 0.167 0.0750 
XDI-
VHR 90 
 
2 4000 25 25 160 0.156  
X-ray 
SCMOS 
 
3 4000 25 25 160 0.156 
0.0750 
 
4 2000 25 25 80 0.313  
5 4000 25 25 160 0.156   
13 
1 4000 25 25 160 0.156 
1.06 
X-ray 
SCMOS 
 
2 4000 25 25 160 0.156  
3 4000 25 25 160 0.156  
4 4000 25 25 160 0.156  
5 4000 25 25 160 0.156  
6 4000 25 25 160 0.156  
7 4000 25 25 160 0.156  
8 4000 25 25 160 0.156  
14 1 4000 25 25 160 0.156 0.94 
X-ray 
SCMOS 
 
15 
1 8000 25 25 320 0.0781 
1.01 
X-ray 
SCMOS 
 
2 4000 25 25 160 0.156  
3 8000 146 100 54.79 1.83 
1.01 
Flat 
Panel 
 
4 4000 146 100 27.40 3.65  
5 4000 146 100 27.40 3.65  
6 2000 146 100 13.70 7.3  
7 2000 146 100 13.70 7.3  
8 2000 146 100 13.70 7.3  
Table 5.3: The number of projections, scan time and movement tolerance of each view as well as 
pixel size and capture time of the detector are described. Notice that with the Hamamatsu Flat 
Panel detector the movement tolerance is several orders of magnitude greater than the Photonic 
Science Fiber Optic Camera XDI-VHR 90 or the Photonic Science Fiber Optic Camera X-ray 
SCMOS. All apparent motions are well above tolerable levels. 
 
 
5.2.1 Seat Modification 
A modification was made to the canine positioning device after the ninth cadaver was 
imaged. The slumping issue was not well understood until after the ninth dog cadaver was 
imaged. To address the issue, a seat was added near the bottom of the Pawsitioner, which 
supported the dog from below. The seat took some of the weight off of the upper harness, and 
provided a firm base for the lower half of the dog. The modification consisted of a pump-jack 
attached to a bicycle seat, with which the height of the seat could be adjusted. A before and after 
picture of the canine positioning device can be seen in Figure 5.10. The modified canine 
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positioning device was used to image the last four canine cadavers, dogs 11-15. Dog ten was 
used to initially test the seat device, but did not undergo PC-CT. The modified seat was also used 
during the imaging of the six live dogs. The modified seat can also be seen in Section 5.4, Figure 
5.13. 
 
 
Figure 5.10: Left: The unmodified canine positioning device. Right: the modified device with 
the seat attached near the base of the Pawsitioner, indicated with a black arrow. The height of the 
seat is adjustable to match the size of the dog being imaged.  
 
5.3 Locating the Prostate 
The canine prostate is typically located equally in the abdomen and pelvic cavity, though this 
would not be the case for neutered dogs, whose prostates would be found exclusively in the 
pelvic canal (39). When the dog is positioned in a near vertical orientation in the canine 
positioning device, the prostate appears to shift downwards into the pelvic cavity. The prostate 
needed to be located before each scan due to the small area that the beam can image, only 10 mm 
x 1 mm. Accurately locating the prostate for imaging presented a significant challenge at the 
CLS that was eventually overcome through experimentation with different locating methods. 
With experimentation with these methods the prostate can now accurately be centered in the 
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beam before scanning is initiated. This is an improvement over the first cadaver imaged, where 
the imaging area was only assumed to contain the prostate. This section covers the external and 
internal methods of locating the prostate for PC-CT in the canine positioning device. Locating 
the prostate occurs in two sequential steps, the external then internal methods. The external 
methods can be thought of as rough positioning of the prostate within the imaging field of view, 
and the internal methods as fine-tuning of the position. 
There are two positioning lasers located within the imaging hutch on the BMIT-ID beamline. 
These two lasers are positioned on walls perpendicularly to one another, and project a straight 
line that divides the hutch into halves.  The intersection of the two lasers occurs at the center of 
the stage rotation. Therefore, these lasers can be used to position a sample accurately in the 
center of rotation for the stage. When the canine positioning device is mounted onto the stage in 
the hutch, the lasers can be used to align the center of the dog roughly in the center of rotation 
for the stage. This rough centering is accomplished using the x-y stages located at the bottom of 
the positioning device, which can be adjust to ±10mm in both the X and Y dimensions. To 
simplify the locating procedure, the dog can be thought of as a near perfect cylinder, with the 
prostate being located near the center. Therefore, if both the lasers travers the dog down the 
center line, the prostate should be roughly centered in the beam. Although this external method 
aligns the transverse abdominal plane of the dog in the center of rotation (referred to as the X and 
Y dimension), it does not address the height at which this plane traverses the prostate within the 
dog (referred to as the Z dimension).  The X and Y dimensions are the width and length of the 
prostate cross section, respectively, while the Z dimension describes the length of the prostate in 
the dorsal section as seen previously in Figure 3.8 and 4.1. The location of the prostate can be 
estimated visually when the dog is held within the canine positioning device prior to imaging. 
The imaging hutch has a third laser which projects a plane line parallel to the floor and ceiling at 
the height the beam traverses the stage’s center of rotation. Using these three lasers, the X, Y, 
and Z dimensions of the approximate prostate location can be centered in the beam.  
Prior to imaging, internal localization methods can be employed to increase the 
likelihood that the prostate will be located within the imaging field of view. A key anatomical 
feature to help locate the prostate for imaging is the urethra. The urethra traverses the prostate in 
its entirety, both in canine and human prostates, and opens into the bladder at the cranial end of 
the prostate. A Foley catheter can be inserted into the urethra through the penis of the dog.  
When the balloon of this Foley catheter is inflated it will secure the catheter at the neck of the 
bladder just cranial to the prostate; locating this catheter balloon can be used to internally locate 
the prostate with the help of the X-ray beam. Foley catheters have two separate channels running 
down their length, one for draining urine from the bladder with openings at both ends, and one 
with only one valve opening used to inflate a balloon near the tip of the catheter. In clinical 
setting the Foley catheter’s balloon can be inflated once placed to prevent the catheter from 
accidentally being removed from the bladder. The inflated balloon is too large to pass from the 
bladder down the urethra, and therefore the catheter remains in the neck of the bladder, just 
cranial to the prostate. The inflated Foley’s catheter balloon was used for the internal method of 
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localizing the prostate for PC-CT imaging. Iodine contrast agent, in the form of diatrizoic acid, 
was injected into the balloon of the Foley catheter which allowed the neck of the bladder and 
urethra to be visualized using X-rays. The diatrizoic acid was purchased from AK Scientific, Inc. 
California, under the brand name H919, with a concentration of 98% (106). Two milliliters were 
injected into the Foley catheter balloon. The contrast is very visible due to the higher X-ray 
absorption of iodine compared to soft tissues at the same photon energy. The mass attenuation 
coefficient of iodine at 50 keV is 12.32 cm2/g, while soft tissue’s is only 0.22 cm2/g 
(78).Therefore, the iodine contained within the catheter is very visible when images are captured. 
Additionally, the catheter prevents the iodine contrast from diffusing through the tissues 
including into the prostatic ducts. When using a Foley catheter to administer contrast agent, the 
balloon filled with contrast agent can be visualized at the neck of the bladder, and therefore the 
prostate should be located caudally to its position. This method can be seen in Figure 5.11, where 
the white arrow indicates the Foley catheter balloon, and a white box indicates the location of the 
prostate. The final step in locating the prostate is to rotate the dog 90-180°, while insuring that 
the Foley balloon catheter remains within the field of view; this is used to confirm that the 
prostate itself will remain in the field of view throughout imaging. If the balloon moves too far 
away from the center of the image the stages must be adjusted accordingly to re-center it. 
 
 
Figure 5.11: A tomographic projection from the first of the six live dogs imaged. The dark semi-
circle indicated with a white arrow is the balloon of the Foley catheter filled with iodine contrast 
agent, stuck within the neck of the bladder. The prostate is located just below, in the white box, 
but cannot be seen directly in this image due to the poor soft tissue contrast. 
 
Due to the small vertical view size of the images captured on the BMIT-ID beamline, 
several projections taken at different view heights can be stitched together to create a larger 
radiographic image. These images are referred to as a scout montage, an example is shown in 
Figure 5.12, taken from the sixth canine cadaver imaged. The montage is of 12 tomographic 
projections, taken at the same angle but different heights within the dog’s pelvic region, stacked 
one on top of each other. The view height is 5.5 mm, and captured with the Photonic Science 
Fiber Optic Camera XDI-VHR 90. The pelvic bone and vertebrae can be seen in the montage, 
outlined and indicated with white arrows. Unfortunately, the Foley catheter was not used to 
locate the prostate until the ninth dog imaged so is not available as a localizing landmark for the 
prostate in this image.  
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Figure 5.12: A scout montage from the fifth view of the sixth dog imaged using the canine 
positioning device. The wings of the pelvis are outlined in white, and the vertebrae are indicated 
with white arrows. The bone appears darker than the surrounding soft tissue because of the 
higher X-ray absorption. 
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5.4 Live Dog Imaging 
5.4.1 Overview 
The conclusion of this thesis focuses on the final stage and implementation of the canine 
positioning device, live dog imaging. All of the previous work shown with cadavers was done to 
prepare for the imaging of live dogs. Live imaging was done on six dogs during May 2016. The 
University of Saskatchewan Animal Research Ethics Board, operating in accordance with the 
guidelines set out by the Canadian Council on Animal Care, reviewed and approved the use of 
live animal subjects and animal tissues for the purposes of this thesis. The dogs were held in the 
canine positioning device in a similar way to the cadavers, with the Walkabout™ front harness 
used to secure their upper body into the Pawsitioner. The live dog imaging used the modified 
seat to secure the lower end of the dog, and to help reduce the motion of the dog during 
scanning. The setup of live dog imaging was more complex compared to cadaver imaging due to 
the necessary equipment needed to keep the live dog anesthetized during imaging. Care was 
taken to ensure that each dog did not receive a lethal dose of radiation during imaging, as these 
live dog experiments were meant to be non-lethal. After imaging, each of the dogs were 
recovered from anesthesia and monitored for any signs of acute radiation syndrome. Symptoms 
of acute radiation syndrome monitored for include: red skin, hair loss, bloody and loose stool, 
nausea, anorexia, vomiting, and weight loss (107). None of the dogs became symptomatic post-
imaging. An image of the live dog in the canine positioning device can be seen in Figure 5.13. 
An oxygen tank, intubation tube, anesthetic gas filter, anesthetic, anesthetic ventilator, 
ventilation bag, intravenous (IV) line, saline IV, pressure IV bag, vital monitoring equipment, 
oxygen flow regulator, and various tubing were used during live dog imaging, along with the 
Foley catheter, Walkabout™ front harness, hook-and-loop straps, and the modified seat. 
The oxygen tank used for imaging was a size M3, with 700 L of oxygen sourced from Praxair, 
Saskatoon, SK. The tank is indicated in Figure 5.13 with a yellow arrow. An Easy Dial Reg™ 
oxygen regulator (Precision Medical Inc, Northampton, PA) was used to control the flow rate of 
O2.  Size 9.5, 10 and 11mm cuffed endotracheal tubes were used for intubation, sourced from the 
Western College of Veterinary Medicine (WCVM), Saskatoon, SK. The Fortec 3™ anesthetic 
vaporizer (Cyprane Limited, Yorkshire, U.K.) used is specified for isoflurane 100% (Piramal 
Critical Care, Bethlehem, PA), was used for all dogs. The anesthetic gas filter is a Breath Fresh™ 
charcoal filter sourced manufactured by Jorgensen Labs Inc, Loveland, CO. The re-breather bag 
used for ventilation was sourced from the WCVM, anesthesia department, Saskatoon, SK. A 
three or five-liter bag was used during imaging, depending on the size of the dog. Normosol-r™ 
(Hospira, St. Laurent, QC), 1000 ml, was used as the IV solution for each of the dogs imaged, 
and the IV line used was a Macro-Drip fluid administration set (DeRoyal, Powell, TE). The IV 
bag was pressurized with a Infu-Surg® pressure infusion bag, used to increase IV flow rates 
(Anetic Aid, West Yorkshire, U.K). A B3MVet Next© device (Bionet America Inc, Tustin, CA) 
was used to monitor the dog’s vitals during imaging. This permitted us to tract trends in the heart 
rate and rhythm, O2 saturation (fraction of oxygen saturated hemoglobin relative to total 
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hemoglobin), non-invasive blood pressure monitoring, respiration rate, temperature, and 
capnography (end tidal CO2). The B3MVet Next
© device was modified to broadcast reading 
outside of the BMIT imaging hutch to the control room. 
Imaging of all live dogs was under direct supervision of a veterinarian (Dr. Elisabeth Snead, 
DVM, University of Saskatchewan). Hydromorphone (0.05 mg/kg, 10 mg/mL) and 
Acepromazine (0.02 mg/kg, 10 mg/mL) were used as intramuscular pre-anesthetic medication. 
The dog was induced with a bolus of intravenous propofol (4 mg/kg, 10mg/mL) before being 
intubated and maintained on inhalant gas anesthesia (isoflurane 1-2%). Following this the dog 
was secured into the Pawsitoner using the Walkabout™ front harness and the hook-and-loop 
straps. The Walkabout™ front harness was modified based off of the poor results with the 
cadavers. The size of the harness was increased to cover a larger surface area over the dog, and 
several more straps were sown onto it to provide extra support. The dog was kept anesthetized 
throughout, and secured into the positioning device on the stage within the BMIT-ID imaging 
hutch. The modified seat was used to secure the lower limbs and pelvic region of the dog. The 
oxygen tank, vaporizer, IV drip, and anesthetic gas scavenger were all attached to the base of the 
positioning device, meeting the design requirement of the device. The monitoring equipment was 
attached to the dog at the appropriate locations, and the monitor was secured to the imaging 
platform, indicated in Figure 5.13 with a black arrow. 
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Figure 5.13: An image of a live dog set up for imaging at the CLS BMIT. The oxygen tank, 
vaporizer, IV drip and gas filter are indicated with a yellow, blue, green, and red arrow, 
respectively. The monitoring equipment is indicated with a black arrow. The modified seat can 
also be seen in this image, indicated with a white arrow. 
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5.4.2 Radiation Dose 
The radiation dose delivered was a large consideration during the live dog imaging. X-
rays are ionizing radiation, and can cause damage to living tissues. The damage from X-ray 
exposure has been well documented in both human and veterinary medicine (108), (109).  An ion 
chamber was used on the BMIT-ID beamline to estimate the surface dose rate the dog received 
during imaging. The surface dose rate delivered to the dog (𝐷?̇?) can be estimated by multiplying 
the ion chamber dose rate (𝐷𝑖)̇  by a magnification ratio between the source - ion chamber 
distance (Xs→I = 51m) and the source - sample distance (Xs→S = 55m), and then dividing the 
results by π (110), (111).  
 
𝐷?̇? = (𝐷𝑖)̇  (
𝑋𝑆→𝐼
𝑋𝑆→𝑆
)
2
(𝜋−1) 
 
Previous research lead to the adoption of a two gray (Gy) dose limit for each of the dogs 
during imaging as no symptoms of acute radiation syndrome appear at surface doses below this 
dose (107). The ion chamber dose rate and surface dose rates at the dog are shown in Table 5.4, 
along with the calculated total amount of time the dog could be imaged while not exceeding the 
total dose allowance. The dose received by the dog is contained to the area irradiated by the 
beam, (i.e. the specific area of each view). Each dog was imaged multiple times at multiple 
areas, with no overlap between the irradiated areas to prevent the dose limit from being reached.  
 
Dog 
(𝐷𝑖)̇  
Ion 
Chamber 
Dose Rate, 
 (mGy/s) 
(𝐷?̇?) 
Calculated 
Surface 
Dose Rate 
(mGy/s) 
Calculated 
Maximum 
Scan Time 
Allowed per 
View (s) 
Experimental 
Scan Time per 
View (s) 
Calculated 
Experimental 
Surface Dose 
Delivered per 
View (mGy)  
1 10.0 2.74 729 400 1096 
2 9.30 2.55 784 400 1020 
3 1.14 0.31 6451 186 58 
4 1.18 0.32 6250 186 60 
5 10.0 2.74 729 400 1096 
6 0.6 0.16 12500 20 3.2 
Table 5.4: The experimental surface dose delivered to each of the live dogs imaged at BMIT. 
 
The surface dose of dogs 1, 2 and 5 was the highest of the six dogs imaged due to the use 
of the Photonic Science Fiber Optic Camera X-ray SCMOS to capture the projections. The 
tomographic projections from dogs 3, 4 and 6 were captured with the Hamamatsu Flat Panel 
Detector, and therefore had a lower dose delivered due to the shorter scan time.  All of the six 
dogs received less than the two Gy maximum surface dose allowance, and were successfully 
[5.3] 
 76 
 
recovered from anesthesia, and are currently healthy and free of acute radiation syndrome 
symptoms. Unfortunately, none of the reconstructions from any of the views collected from the 
live dogs show the in situ prostate. Figure 5.14 shows an example reconstruction from dog 5. 
The reconstruction has no soft tissue contrast, while bone is slightly more apparent. All the 
reconstructions from all six live dogs are comparable to Figure 5.14, and show less detail than 
the cadaver dog’s reconstructions.  
 
Figure 5.14: A reconstructed slice from dog 5. There is a large amount of motion blur and 
streaking artifacts (indicated with white arrows), and a no visible prostate area. Bone is 
observable in the bottom left of the image and near the center of the upper left quadrant, 
indicated with black arrows. The urethral catheter is indicated with a yellow arrow. 
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There are several proposed reasons why the reconstruction quality from the live dog 
imaging was poor, including: the general motion artifact issue, unconscious motion (i.e. 
cardiopulmonary (CP) and gastrointestinal (GI) motion), and low signal transmission. Both 
motion artifact and low signal transmission contribute greatly to poor reconstruction quality, 
while unconscious motion has a lesser effect. The motion issue has previously been discussed in 
section 5.2, and was known to be an issue before the live dogs were imaged. Breathing, 
heartbeats, and smooth muscle contraction of the GI tract during scanning could result in motion 
artifact formation in the reconstructions. Some of this unconscious motion can be overcome with 
CP gaiting, a type of monitoring that synchronizes the image capture time with a specific phase 
of the CP cycle. In this way the tomographic projections can be captured when the dog is in the 
same breathing position, thereby minimizing the CP motion effect seen in the tomographs and 
reconstructions (112). Cardiac and respiratory gating would greatly increase scan time, as each 
tomographic projection needs to be captured at the same position of the heart and breathing 
cycle. This was not attempted in this study. There is no effective way to control GI motion, 
though a rectal balloon has been proposed as a potential device. The balloon would be inserted 
into the rectum of the dog and inflated, potentially reducing any motion of the prostate caused by 
motion of the rectum. These rectal balloon have been employed in humans undergoing 
radiotherapy for the treatment of rectal and prostate cancer (113), but no previous research was 
found describing their use with dogs. Low signal transmission is the final proposed issue of live 
dog imaging. Recall from section 3.1.1 that the X-ray transmission through a sample is equal to: 
  
 
 
The thickness (x) is an important factor for live dog imaging, and is one of the reason for 
the poor signal transmission. The transmission of X-rays through the live dogs is shown in Table 
5.5. These transmission values were calculated using the mass attenuation coefficient of soft 
tissue at 90 keV, and the diameter of the dog in the pelvic region. Notice that the transmission 
values are all less than the 10% minimum transmission required for high quality CT 
reconstructions (98). For simplicity sakes the dog is assumed to be a cylinder of uniform mass 
attenuation coefficient. Although the assumption that each dog is a perfect cylinder of 
homogenous mass attenuation coefficient is clearly inaccurate, it does provide an over-estimation 
of the amount of X-ray transmission through the dog. 
 
 
 
 
 
 
[3.1] 
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Dog Diameter (cm) Transmission (I/I0) 
1 18.6 3.13 
2 21.83 1.71 
3 20.83 2.31 
4 18.60 3.13 
5 17.78 3.63 
6 15.36 5.71 
Table 5.5: The transmission (I/I0) of each of the live dogs imaged on BMIT. For simplicity sake 
the dog is assumed to be a cylinder of uniform diameter as indicated. 
 
From Table 5.5, it is apparent that the thickness of the dog is too large for sufficient 
signal transmittance (above 10%). This is called the transmission issue. In clinical CT the 
transmission issue can be overcome by increasing the current of the X-ray tube, thereby 
increasing the flux generated, and the amount of photons hitting the detector (114). 
Unfortunately, the synchrotron storage ring current cannot be modulated to increase the flux 
generated. There is currently no way to increase the flux during PC-CT in real time like in 
clinical CT. The transmission issue is also more complicated due to the non-homogenous nature 
of the mass attenuation coefficient within the dog. While the dog is being imaged there is 
potential for areas to have less attenuation or less thickness than other areas within the beam, 
leading to certain regions of very high transmission. There may also be areas of greater thickness 
or increased mass attenuation coefficients, giving rise to regions of very low transmission. These 
high and low transmission areas can occur in the same tomographic projection. This complicates 
the transmission issue because certain areas of the detector may get over-exposed to X-rays, 
while in the same projection there can be areas of under-exposure. As the dog is rotating through 
the scan, the detector can repeatedly be over-exposed and under-exposed to X-rays, reducing the 
quality of the captured tomographic projections and therefore, the quality of the reconstructions 
as well. Solutions for the transmission and slumping issues have not been found to date resulting 
in poor reconstruction quality in the images achieved in cadavers and live dogs.    
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Chapter 6: Conclusion 
6.1 Overview 
In the past twenty years, synchrotron X-ray imaging has emerged as a novel way for high 
resolution imaging of biological tissues and samples. The specific objective of this thesis was to 
design, develop, and implement a canine positioning system for the Biomedical Imaging and 
Therapy – Insertion Device beamline, capable of imaging in situ dog prostates in both cadaver 
and live dogs. Chapter one introduced the idea of using PC-CT to image in situ canine prostates 
as a way to determine cellular morphologies, with the hope of eventually using PC-CT as a 
diagnostic tool for human PCa. Chapter two examined the current understanding of human and 
canine prostate anatomy and pathology, as well provided justification for the use of dogs as a 
model for human PCa. In chapter three, the general information of radiology and synchrotron 
imaging was discussed, and background was provided on the use of PC-CT for in situ imaging.  
Chapter four presented the design process for the canine positioning device, along with 
the background information of the detectors used for PC-CT. The canine positioning device was 
successfully designed and manufactured, and meet the specifications required of the design. In 
chapter five the implementation of the device was discussed, including cadaver and live dog 
imaging. The device failed to properly immobilize the dogs during imaging, resulting in severe 
motion of the dog. The motion artifact issue, along with the transmission issue, generated CT 
reconstructions of poor quality, and prevented the in situ prostate from being visualized at this 
time.  
 
6.2 Future Directions 
The motion and transmission issue must be addressed before any future research can be 
conducted with the canine positioning device. The modified seat will be revamped and improved 
to better immobilize the dog within the device. Once the motion artifact issue is addressed, work 
can be done to correct the transmission issue. It is anticipated that ultimately this device will also 
be able to be used to image areas of the dog other than the prostate. 
The canine positioning device can be used to compare in situ canine prostates PC-CT to 
clinical diagnostic tools, such as magnetic resonance imaging, CT, ultrasound, and positron 
emission tomography-CT. Studies can be conducted on experimental induction of BPH and PCa 
in dogs, with the device used to collected PC-CT reconstructions of control and treatment 
groups. Accomplishing in situ imaging of canine prostates is the first step towards in situ 
imaging of human prostates. 
 
6.3 Conclusion 
 This thesis has laid the ground work for canine imaging on the Biomedical Imaging and 
Therapy – Insertion Device beamline at the Canadian Light Source. The design and 
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implementation of the device are described, along with the issues discovered and addressed. 
Unfortunately, no in situ canine prostates were seen post-imaging in reconstructions. This is a 
significant setback in the potential use of PC-CT as a diagnostic tool for human PCa, but is 
nonetheless an important step forwards in both prostate cancer and medical imaging research. 
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